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The work reported in this thesis was part of a larger project concerned with
investigations of pasteurellosis in sheep, and consequently some of the experimental
findings were obtained in collaboration with my colleagues at the Moredun Research
Institute. Nevertheless, most of the work presented in this thesis was carried out by
myself, and where conjoint experiments were necessary, a full role was played in the
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Tustewella haemo/yfica serotypes causing pneumonic pasleurellosis in sheep and goats
in Malaysia, assess the efficacy of a novel /'. haemolytica vaccine in field trials and to
isolate, characterise and assess the immunological significance of the polysaccharide
capsule of /'. haemolyiica A2. The serotyping study indicated that there was little
difference in the relative frequency of occurence of A serotypes in the UK and in
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passive protection of lambs against A2 infection is obtainable.
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Pneumonic pasteurellosis in sheep is an important disease and causes serious
economic losses to the livestock industry throughout the world. In the United Kingdom
a survey conducted by the Ministry of Agriculture, Fisheries and Food (MAFF, 1964)
showed that 82% of all carcasses referred to Veterinary Investigation Centres showed
evidence of pneumonia. The veterinary investigation report for Scotland for the years
1976-1977 showed that most sheep pneumonia is related to pasteurellosis (Veterinary
Investigation Diagnosis Analysis Report, 1977). The organism most frequently isolated
from the pneumonic lungs is P. haemolytica (Gilmour, 1978a). In South Africa, Van der
Veen and Zumpt (1976) recovered P. haemolytica from 13 out of 36 outbreaks of
pneumonia and P. multocida from six. Dennis (1974) indicated that P. haemolytica was
the main cause of perinatal Iamb mortality in Western Australia. P. hacmolytica was also
most commonly isolated from healthy flocks in United States of America (Frank, 1982)
and pneumonic lungs in New Zealand (Prince et al., 1985).
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Pneumonia has also been associated with other types of bacteria such as
Escherichia coli, Staphylococcus spp., Streptococci spp., Pseudomonas spp. and
Fusobacterium necrophorum, but they are thought to be ofminor importance.
Pneumonic pasteurellosis is not restricted to sheep and goats, but can infect a
wide range of animals such as cattle, swine, horses and fowl. Since the early 1900s
bovine pneumonic pasteurellosis has been recognised as a major economic problem to
European and North American cattle industries (Yates, 1982). McKercher (1978)
estimated losses in the United States due to the disease also known as "shipping fever"
at 76 million dollars in 1972 and in 1981 the annual losses amounted to approximately
800 millions dollars (Drummond et al., 1981). The involvement ofP. haemolytica in
the cattle pneumonia has been well documented (Carter, 1967; Gilmour, 1978).
While some efforts have been directed towards minimising exposures to certain
factors commonly associated with the disease, vaccination is accepted as the most
effective and practical method of control. Numerous studies undertaken over the past
decades have evaluated the efficacy of Pasteurella vaccines composed of whole
organisms and or various sub-cellular preparations. In spite of these efforts, vaccines
have had dubious beneficial effects and pneumonic pasteurellosis remains one of the
most significant causes of loss in sheep population of the United Kingdom (Gilmour,
1978) and Malaysia ( Mohamad, unpublished data, 1993).
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Gilmour et al. (1983) showed that protection with the available commercial
vaccines is variable with little or no protection being provided by the vaccines containing
sodium salicylate extracts (SSE) against heterologous serotype challenge. This indicates
that either the immunising power of the commercial vaccines is insufficient to protect
against the disease or the vaccines might not contain the appropriate range of serotypes
and that the antigens might not be incorporated in the optimum way.
A number of antigens have been assessed as potential immunogens. Gilmour et
al. (1979) has shown that vaccines prepared from extracts ofbacterial cells do protect
sheep against experimentally produced pneumonic pasteurellosis. The homologous
vaccines incorporating sodium salicylate extracts (SSEs) have protected sheep against
disease caused by biotype A serotypes 1, 6 and 9. However, vaccines containing SSE,
or heat-killed cells of serotype A2 (the serotype of most importance and which is
responsible for the majority of the outbreaks of ovine pasteurellosis) have been less
effective immunogens in mice, rabbits and sheep (Gilmour et al., 1983; Evans et al.,
1979b; Donachie et al, 1986). One reason for this may be the poor immune response
to the serotype-specific capsular polysaccharides which arc a common constituent of
host membranes (Adlam et al., 1987). A more detailed knowledge of the important
antigens involved in stimulating protection could lead to improvement in the production
and the efficiency of existing commercial vaccines. Recent work by many investigators
has determined that a number of antigens are potential immunogens; these include:
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0 Capsule
ii) Outer Membrane Protein (OMP)
iii) Lipopolysaccharide (LPS)
iv) Leukotoxin (cytotoxin)





1.2 Pasteurellosis in sheep and goats with reference to Malaysia.
Malaysia is a tropical country with a total land area of 329 758 km2. She has
two main weather seasons, the dry season from Mac to August and the rainy seasons
from October to Febuary. The temperature varies between 23°C and 33°C with an
average of about 26°C.
In 1993, the estimated ruminant population was 689,288 cattle, 110,149 buffallo,
244,023 sheep and 277,065 goats ( DVS Report, 1993). Extensive or free-range
grazing systems in rural areas, and semi-intensive and intensive systems in organised
farms are used in cattle, sheep and goat husbandry. For sheep and goats, integration
with plantation crops such as rubber and oil pallm is expanding. The animals are allowed
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to graze native grasses under the tree crops for about 7 hours. They are housed at night
where water and supplementary feed are provided.
The main causes of sheep and goat mortality in Malaysia are pneumonic
pasteurellosis, haemonchosis, pregnancy toxaemia and blue tongue. Pneumonic
pasteurellosis is by far the most important and accounts for more than 35 percent of
sheep mortality (Wan Mohamad et al.. 1988). Another report estimates that the
pneumonia-bluetongue complex causes more than 50 percent of deaths in newly
imported sheep in Malaysia (Hadi, 1988). Evidence provided by various investigators
indicates that two species are the main causative organisms of pasteurellosis. These are
Pasteurella haemolytica and Pcisteurellci multocida, with the former being by far the
more significant (Gilmour, 1978a).
Pasteurellosis affects sheep and goats of all ages under all management
conditions. Pasteurella species are normal flora in the upper respiratory tract and tonsils
ofmost sheep and goats. Management practices such as castration, docking or infections
with para-influenza virus, mycoplasma, mould or the agent of tick-borne fever are
among the predisposing factors thought necessary to precipitate pasteurellosis (Gilmour
et al., 1980). The hot humid tropical climate ofMalaysia, with unpredictable rainy spells
and monsoons, aggravates the condition to the disease. Depending on these
predisposing factor(s) and the strains of the organisms involved the disease can be acute
or hyperacute as well as chronic (Gilmour et al., 1980).
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In Malaysia, pneumonic pasteurellosis may be regarded as a clinical manifestation
of an infection which occurs as the result ofvarious stress factors such as transportation
of sheep and goats from place to place. There have been no reported attempts to
determine the incidence of the disease which occurs under the type of management
systems used in Malaysian sheep farms. The disease occurs frequently in young lambs
and kids with the highest incidence during or shortly after the rainy season (personal
observation). In severe outbreaks of pasteurellosis, more than 50% of the sheep in a
flock may be affected and death rates are usually more than 25% (Mohamad, 1993;
unpublished data).
Sheep and goat pasteurellosis in Malaysia is usually caused by P. haemolytica
and occasionally by P. multocidci (Sheikh Omar et al., 1989). The occurence and
severity of the disease may depend on a series of complex interactions between several
infectious agents, environmental factors, and the immunological status of the lamb.
Although in Malaysia antimicrobial agents have been extensively used to treat
pneumonic pasteurellosis, vaccination has been accepted and is becoming more popular.
The types ofvaccines used include formalin-killed whole cell vaccines, extracts ofwhole
cells or live attenuated vaccines. Several kinds of commercially prepared broth vaccines
have been used in Malaysia, but their efficacy in the field has been questioned (Wan
Mohamad et al. , 1988).
Some of the commercial vaccines used widely in Malaysia are HeptavacR
(Hoechst, UK) and CarovacR (Pitman-Moore, UK). Despite the widespread use of the
vaccines, outbreaks of pasteurellosis still happen and there are no indications that the
prevalence ofthe disease is diminishing (Gilmour, 1980). Indeed, vaccinated animals are
frequently more apparently susceptible to the disease than their non-vaccinated
counterparts ( Shewen & Wilkie, 1982).
1.3 Objectives of the Study
This thesis concentrates on P. haemolytica serotype A2 as the main cause of
ovine and caprine pneumonic pasteurellosis. The first part reviews the literature
associated with P. haemolytica, the disease and prevalence and distribution of serotypes
in Malaysia. The second part is concerned with the testing of a new P. haemolytica IRP
vaccine (Ovipast-9-IRPR, Hoechst, UK) for its efficacy on Malaysian sheep farms. The
final part deals with the isolation, characterisation, purification and assesment of the
immunological significance of the polysaccharide capsule ofP. haemolytica A2.
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CHAPTER 2.0 LITERATURE REVIEW
2.1 The characterisation of P. haemolytica
2.1.1 The Bacterium
The first description of the organism was that of Jones (1921) as a short,
encapsulated Gram-negative, non-motile cocco-bacilli (Plate2.1). Colonies on blood agar
are flat and translucent, 3-5 mm in diameter after 48 h incubation and show a weak
haemolysis on 7% sheep blood agar (Plate 2.2). The organism is aerobic and
facultatively anaerobic. It is oxidase and catalase positive and attacks sugars by
fermentation yielding small amounts of acids without producing gas (Cowan & Steel,
1974). It can be distinguished from other members of the genus Pasteurellla using
the characteristics shown in Table 2.1.
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Plate 2.1. Colonies of P. haemolytica A2; encapsulated, the most
predominant field isolates in pneumonic pasteurellosis.
Plate 2.2. Colonies of P.haemolytica A2 on blood agar plate ( small
colonies arA arrowed; the larger colonies are T strains).
The cell measures about 0.7 ^m in diameter.
Table 2.1. Differentiation of P. haemolytica from other Pasteurella species.
1. P. haemolytica causes a narrow zone of haemolysis on 7%
ovine or bovine blood agar. Other Pasteurella species are
not haemolytic.
2. P. haemolytica grows on MacConkey agar whereas
other Pasteurella species will not.
3. P. haemolytica is unable to produce urease and indole
where as other Pasteurella species do.
2.1.2 Biotyping
Strains of P. haemolytica can be classified into two biotypes, A and T,
differentiated on the basis of several in-vitro biochemical criteria including carbohydrate
fermentation activity (Smith, 1961), nucleic acid homology (Biberstein and Francis,
1968) and antibiotic sensitivity (Biberstein and Kirkham, 1979).
Smith (1961) investigated the biochemical characteristics of P.
haemolytica and showed that in sugar fermentation two distinct biotypes (A and T) of
P. haemolytica can be differentiated. Biotype A isolates mainly ferment arabinose and
biotype T isolates mainly ferment trehalose. These two biotypes are responsible for
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different clinical forms of pasteurellosis in sheep, goats and cattle. The A biotypes are
associated with pneumonic pasteurellosis, whereas the T biotypes have been associated
with systemic disease in young lambs (Smith, 1961).
The ability of strains to ferment xylose, salicin and lactose also assist in
differentiating between biotypes. Biberstein (1978) showed that A biotypes are usually
salicin negative, xylose positive and lactose positive (apart from serotype A2 strains
which are usually salicin positive and negative for xylose and lactose).
In terms of antibiotic susceptibility. Smith (1961) showed that biotype
A isolates are generally more susceptible to penicillin than those of biotype T. This has
been confirmed by Biberstein and Kirkham (1979) who showed that biotype A serotypes
also had an increased in vitro susceptibility to ampicillin, cephalotin, chloramphenicol,
tetracyclin, erythromycin and nitrofurantion. A strains are also more susceptible to
growth inhibitors such as fuchsin, methylene blue and brilliant green (Olmos and
Biberstein, 1979).
The biotype A isolates may be differentiated from biotype T isolates
by the colony morphology on blood agar. At 24 h, biotype A isolates appear as evenly
coloured grey colonies, whereas more of biotype T produce larger colonies with large
brownish centres (Adlam, 1989 and Plate 2.2). In DNA-RNA hybridization experiments,
Biberstein and Francis (1968) have shown that there was a low degree of relationship
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between representatives of A and T strains, but a high relationship between the two A
strains tested. Davies (1994) have recently shown that the biotype A may be
differentiated from the biotype T from the analysis of their OMP and LPS profiles using
the sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western-blotting techniques.
The genome ofPasteurel/a species has also been studied in attemps to
establish relationships between strains. More recently, nucleotide sequencing has
proved to be a superior method ofgenome analysis and strain differentiation. The cloned
genes could be used as specific probes in hybridization studies into the organization and
distribution of the virulence antigens in the bacteria. Lo, (1994) showed that the A and
T biotypes carry a very different genetic organization for these genes.
2.1.3 Serotyping
Biberstein el aI. (1960) first developed an indirect haemagglutination
assay (IMA) to subdivide biotypes A and T strains into different serotypes. This method
of serotyping relies on the differences in capsular polysaccharides present on the strains
and to date 17 serotypes have been identified with thirteen of these belonging to the A
biotype: Al, 2, 5, 6, 7, 8, 9, 11, 12, 13, 14 and 16 and four belonging to the T biotype
T3, 4, 10 and 15 (Fodor et al., 1987; 1988; Younan et a!., 1995). Adlam el al., (1984,
1985a, 1985b, 1986, 1987) have purified and characterised five of the serotype specific
capsular polysaccharides.
A number of isolates cannot be serotyped using these methods. Fraser et
al. (1982) reported that 6-11% ofovine isolates were untypable. These strains have been
isolated from both healthy and diseased sheep. Quirie et al. (1986) noted that the
percentage of untypable strains was higher in cattle and that most isolates were
associated with the nasopharynx of healthy animals or with the female genital tract
(including the placenta and foetus), udder and milk. AarslefT et al. (1970) showed that
these untypable strains generally belong to the A biotype and that their negative reaction
in the IHA test is due to lack of the soluble antigen responsible for serotyping.
According to Biberstein (1978), untypable strains probably represent unencapsulated
mutants and probably belong to the A biotype since they exhibit sugar fermentation
patterns more typical of A strains than of T strains.
Serotyping of I', haemolytica strains can also be carried out by different
techniques, which include a rapid plate agglutination method developed by Frank and
Wessman (1978) where direct agglutination of the bacterial cells can be carried out on
a microscope slide. The method suggests that the serotyping antigen is a polysaccharide
and present on the surface of the bacterium. Chengappa et al. (1984) described counter-
immune electrophoresis (CIE) method which involves two dimensional electrophoresis
that seperates antigens by their charge in the first dimension then visualises them by
precipitation against specific antiserum in the second dimension. Other methods include
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a modification of IHA techniques by the use ofmicrotitre trays (Shreeve el al. 1972) and
glutaraldehyde fixed-ox cells (Fraser el al., 1982, 1983).
2.2 P, haemolytica Antigens
Structurally P. haemolytica resembles other Gram-negative organisms in having
several cell wall associated components or products which help it to become established
during an infection (Figure 2.1). In addition to serotype specific capsular polysaccharides
it possess lipopolysaccharides, outer and inner membrane proteins and peptidoglycan
(Adlam, 1989). A glycocalyx and umbrae have been reported recently. Two types of
fimbrae or pili, one thick and rigid and the other thin and flexible are present on the
surface of Al serotype organisms grown in agar (Morck el al., 1987; Potter el al.,
1987). Apart from cell wall associated antigens, the organism produces enzymes and
proteins which include a potent and specific cytotoxin. a haemolysin, and extracellular
enzymes including neuraminidases and proteases. Many aspects of the structure and
function of these antigens remain to be elucidated.
The staicture and function of the bacterial cell surface antigens, as well as their
role in pathogenesis and immunity are subjects of great interest to scientists, as this
knowledge is essential for the development of effective Pasleurella vaccines. A number
of antigens have been assessed as potential immunogens and a number of advances have
been made in the formulation of possible future vaccines. The important antigens which
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Figure 2.1. Schematic representation of the Gram-negative cell envelope.
LPS - Lipopolvsaccharide LP - Lipoprotein






Plate 2.3. Electron micrograph of the P. haemolytica serotype A2,
showing the location of capsular materials (Arrowed).
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have been studied are briefly mentioned here, but this thesis will concentrate on the
capsule and outer membrane protein of P. haemolytica serotype A2 as future
components of a Pasteurella vaccine.
2.2.1 Capsule
P. hacmolytica possesses a soluble, heat stable external capsule composed
of extracellular polysaccharide. It is responsible for serological specificity and has long
been recognised as playing a role in the pathogenicity of the organism (Biberstein et al.,
1960). It is loosely attached to the bacterial cell and can be removed by vigorous shaking
or alkali treatment. The capsule is very hydrated, being only 1-2% polysaccharide and
probably functions as a moisture and ion trapping layer around cells and may inhibit
phagocytosis (Donachie, 1984a). Being negatively charged it can be stained with
ruthenium red (Howard & Gourlay. 1974) or labeled with polycationic ferritin and
examined by electron microscopy (Weiss et al.. 1979; Gilmour et al.. 1985) (Plate 2.3).
Exopolysaccharide can be divided into homopolysaccharides and
heteropolysaccharides depending on the composition and the complexity of the sugar
groups in the polymer. Neutral hexases such as D-glucose, D-galactose and D-mannose
are frequently present in the capsule. Sialic acid polymers, a type of homopolysaccharide
(N-acetylneuraminic acid or NANA), are found in P. haemolytica serotype A2, Neisseria
meningitidis, Escherichia coli K1 and Moraxella liquafaciens (Bovre et al., 1983). It is
a colominic acid structure a-(2-*8)-linked polymer ofN-acetylneuraminic acid or NANA)
(Figure 2.2). In mammals, linear polymers of a-(2->8)-linked NANA form surface
glycoproteins of mammalian neural cells (Finne et al., 1983), neural cell adhesion
molecules (Finne et al., 1985) and gangliosides (Soderstrom et al., 1984).
Figure 2.2^Structure of capsular polysaccharide of P. haemohtica A2;
an a (2~8)-linked N-acetyl neuraminic acid (NANA).
The polymers of NANA confer the property of invasivesness to E: coli
Kl (Schiffer et al.. 1976). In infant rats, E. coli K92 strains induce bacteremia and
meningitis after intestinal colonisation (Glode et al., 1977). Passive administration of as
little as 1 //g of H 46 or human immunoglobulin M monoclonal antibodies specific for
oc-(2-*8)-linked NANA protected the infected rat pups from bacteremia and death.
Unfortunately this polymer has been shown to be poorly immunogenic
when used as a vaccine component against N. meningitidis group B disease in human
beings (Lifely et al., 1987) and did not induce an antibody response in lambs (Adlam et
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al., 1987). The polymer alone, or complexed to homologous outer membrane protein,
induced low transient levels of IgM antibody in mice and is relatively short lived.
(Moreno et al, 1983). Covalent attachment of this capsular polysaccharide to a
heterologous protein failed to elicit antibody to this antigen. Hypotheses have been
postulated to explain the poor immunogenicity of this polysaccharide, such as sensitivity
to the host neuraminidases, cross reactivity with self antigens and loose configuration
of the purified polysaccharide ( Lifely et al., 1987).
Although there exists controversy regarding the protective antigens of
group B N. meningitidis, there is little doubt as to the importance of its capsular
polysaccharides as virulence factor. Lifely et al. (1987) have identified the capsule of
N. meningitidis group B and E. co/i K1 as a virulence factor and protective antigen.
Using monoclonal antibodies with specificities for N. meningitidis group B capsule and
outer membrane protein-polysaccharide complex meningococcal vaccine, (Donachie
1991, unpublished data) has shown protection against P. haemolytica A2 challenge in
mice. These results prompted research to formulate a P. haemolytica A2 vaccine with
a similar composition to the meningococcal vaccine to evaluate its efficacy against
experimental pasteurellosis.
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2.2.2 Outer Membrane Protein (OMP)
The proteins of the outer membrane are arranged as shown in Figure 2.1.
They are embedded in the lipid bilayer and typically make up almost half the dry weight
of an outer membrane. Nikaido and Nakae (1979) in analysing the outer membrane
protein found that the outer surface of the membrane is 59% protein and 41% LPS while
the inner surface composed of 53% phospholipid and 47% protein.
The study of the protein of the outer membrane has been well
documented and many reviews are available in the literature (Di Rienzo et al., 1978).
Techniques are available to visualise and resolve the protein components of the outer
membrane and purification of the proteins has been achieved by selective solubilization
with detergents such as Sarkosyl (Filip et al.. 1973), by gel permeation chromatography
or by electroelution from the polyacrylamide gel following Sodium Dodecyl Sulphate
Polyacrylamide Gel Electrophoresis (SDS-PAGE). Commassie blue or silver staining
(Tsai & Frasch, 1982) ofouter membrane fractionated on SDS-PAGE reveals the OMP
profile of the bacterium, which normally comprises several heavily stained bands (the
major OMPs) and numerous minor bands. Knight et al. (1990) have shown that
envelopes isolated from P. haemolytica biotype A, P. haemolytica biotype T and P.
multocida could be differentiated by their SDS-PAGE profiles. The authors further
showed that different isolates of the same P. haemolytica A serotype always generated
very similar SDS-PAGE profiles and P. haemolytica T envelopes gave simpler SDS-
20
PAGE profiles which were typified by distorted bands in the high molecular mass region.
Thompson & Mould (1975), who analysed phenol/acetic cell extracts ofP. hacmolytica
by SDS-PAGE and showed differences in the profiles of extracts derived from A strains
and T strains. E. coli outer membrane protein has received most attention and work by
Ames (1974) showed that between 36 and 66 protein bands could be identified in its
outer membrane ofwhich d or 5 appeared to be major components. Investigation into
other species such as Salmonellla typhimnrium and Neisseria gonorrhoeae have shown
similarities in that 4-5 major proteins are always present (Bragg and Hou, 1972;
Heckels, 1977). Squire et al. (1984) have separated and purified membranes of A1
serotypes and showed that major OMP had molecular masses of 30 and 42 kDa.
2.2.3 Lipopolysaccharide (LPS)
The biological activities of LPS as a virulence determinant in
Gram-negative bacteria have been thoroughly investigated. LPS confers resistance to
complement and bactericidal activity of serum. It stimulates the release of mediators
involved in the inflammatory response, the coagulation pathway and damage of tissue
(Morrison and Leive, 1978). Keiss et al. (1964) estimated that between 12 and 15% of
dried cell weight ofP. haemolytica consisted of LPS. A study conducted by Tsai et al.
(1982) showed that water extracts of P. haemolytica when compared by crossed-
immunophoresis revealed a distinct serological difference between LPS molecules
extracted from different serotype strains.
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extracted from different serotype strains.
The LPS ofP. kaemolytica has similar biological activity to the LPS of
other Gram-negative bacteria such as S. typhymurium and E. coli.. It showed a similar
endotoxic effect when given to chick embryos and in limulus amoebocytelysate tests
(Rimsay et al., 1981). It has been shown that P. haemolylica LPS binds to sheep lung
surfactant and causes lesions similar to those found in natural disease (Brogden et al.,
1986). The bactericidal effect of immune sheep sera to A2 serotype can be removed by
absorption with purified LPS, indicating that this is the target antigen and that it is
important in immunitiy as well as in pathogenesis (Sutherland, 1988). Sutherland et al.
(1990) also reported that LPS composition differs between in vivo grown bacteria and
those grown in vitro, and these differences are associated with diffferences in relation
to opsonophagocytosis and complement-dependent killing. LPS can also stimulate
TNF-a release from bovine alveolar macrophages (Bienhoff et al., 1992).
2.2.4 Leukotoxin (cytotoxin)
The leukotoxin ofP. haemolytica has specificity for leukocytes of sheep
(Sutherland et al., 1983), cattle (Benson et al., 1978) and goats (Chang et al., 1987) and
has been recognised as a major pathogenic determinant ofP. haemolytica. It has been
shown to be sensitive to heat, trypsin, periodate, amylase and extremes of pH (Baluyut
etal., 1981; Chang et al., 1986; Sutherland and Redmond, 1986). The molecular weight
was reported to range between 100 and 300 kDa (Himmel et al., 1982; 1985; Mosier
et al., 1986; Chang et al., 1986) and it is produced by all serotypable and
non-serotypable strains ( Shewen and Wilkie, 1983a; Sutherland and Donachie, 1986;).
The former also showed that rabbit antiserum cross-neutralised the leukotoxin of
different serotypes, indicating some homogeneity. Active growing cells of P.
haemolytica have been shown to secrete leukotoxin, which can be cloned and produced
using recombinant techniques. Strathdee and Lo (1987) have shown that the P.
haemolytica leukotoxin genes and the corresponding protein share extensive homology
with E. coli alpha haemolysin (50.3% of the amino acid residues are identical).
Production of leukotoxin in the early stages of infection is important as it probably
enables the bacterium to invade the alveolar macrophage. Neutralising antibodies have
been demonstrated in the serum of sheep (Sutherland et al., 1983) and are thought to
be important in immunity.
2.2.5 Iron-Regulated Proteins (IRPs)
Some important immunogenic components such as iron-regulated
proteins (IRPs) arc expressed by cells in vivo and not by cells cultured on a complete
medium in vitro (Morck et al., 1991). Neilands (1982) have reported that these proteins
are strongly expressed under conditions where iron availability is restricted as is the
case in the animal host in vivo or in iron-depleted medium in vitro. Two IRPs of 70 and
100 kDa were present in the outer membrane of P. haemolytica A2 cells isolated
directly from the pleural fluid of infected sheep (Donachie & Gilmour, 1988). These
proteins were expressed at a low level in A2 cells grown in vitro on iron-replete
medium, but could be induced to a higher level of expression when the cells were grown
in a medium which had been depleted of iron with an iron-chelating agent. Serum from
convalescent sheep contained antibodies to both of these IRPs indicating that they were
expressed in natural infection and were immunogenic. P. haemolytica IRPs are now
known to bind ruminant transferrin and thereby obtain iron directly from the host
system (Ogunnariwo & Schryvers 1990). Antibodies raised against IRPs may act
immunologically by blocking the binding of transferrin leading to iron deprivation in the
bacterium and thereby allowing the host to remove it.
2.2.6 Fimbrae
At least two types of fimbrae or pili, one thick and rigid and the other
thin and flexible, were isolated from P. haemolytica serotype A1 grown in agar (Morck
et al., 1987; Potter et a/., 1987). These fimbrae can be isolated from bacteria grown
under routine conditions for example in brain heart infusion broth at 37°C. Potter et
al. (1987) reported that it may be possible to enhance fimbrial growth by subjecting
various bacteria to elevated temperature or increased iron levels. The fimbrae are
approximately 12 nm in diameter and vary in length from 100 nm to more than 500 nm.
They may act by mediating adhesion to mucosal surfaces.
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2.2.7 Neuraminidase
The majority of A serotype strains of P. haemolytica, but not the T
serotype strains were found to produce the enzyme neuraminidase when grown
overnight on blood agar (Frank and Tabatabai, 1981). Neuraminidase was initially
found to be cell-associated, but Otulakowsky et al. (1983) demonstrated the enzyme in
crude leukotoxin prepared from culture supernates. The significance ofP. haemolytica
neuraminidase in pathogenicity is unknown, but Gottschalk (1960) demonstrated that
removal of the terminal sialic acid residue from salivary glycoprotein by the enzyme
resulted in a loss of viscosity and adhesiveness, which could impair the protective
function of the mucosal surface. The effect of this neuraminidase on A2 capsular
polysaccharide is unknown.
2.2.8 Haemolysin
Haemolysin production may be one strategy used by P. haemolytica for
acquiring iron from host red blood cells. Little is known about the haemolysin produced
by the bacteria. Chang et al. (1987) demonstrated that its production does not appear
to be plasmid mediated. It is generally believed that the leukotoxin is the haemolysin
(Strathdee & Lo, 1987).
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2.2.9 Protease
Otulakowsky et al. (1983) demonstrated that P. haemolytica produces
a protease enzyme specific for the sialoglycoprotein on human red blood cells. This
enzyme activity was demonstrated in most strains ofP. haemolytica culture supernatant
cytotoxic for bovine pulmonary macrophages.
2.3 Mouse model of disease
Experimental reproduction of sheep pasteurellosis is costly and the numbers of
animals available is limited and seasonal. A model of the disease in laboratory animals
would be advantageous, but unfortunately P. haemolytica is relatively non pathogenic
for laboratory animals unless large numbers of organisms are used and thus increasing
the possibility of endotoxin shock (Smith, 1959). Olitzki (1948) has described the use
of mucin to enhance the virulence of organisms which are weakly or non-pathogenic
when inoculated into mice. Smith (1959) developed two successful methods of
infecting mice with P. haemolytica. One was an intra-cerebral inoculation of the
bacteria suspended in hydrolysate solution which resulted in multiplication of the
bacteria and death. The other method was by infecting the mice with a suspension of
the bacteria in mucin intraperitoneally. This resulted in septicaemia and death of the
mice within 48 hours. This model of the disease has proved to be most valuable and
Smith (1959) used it to demonstrate passive protection and later active immunisation
ofmice.
Biberstein and Thompson (1964) also used this model to investigate the roles
ofcapsular and somatic antigens in immunity to P. haemolytica. The results suggested
that capsular antigens play the major role in immunity with somatic antigens being of
minor importance. However Knight et al. (1969) using the same model could not repeat
the work and anomalies were found, one of these being that greater immunity was
conferred by antigenically unrelated serotypes.
Cameron and Smit (1970) in trying to reproduce infection of mice in
P. haemolytica using this method, also failed to get consistent results. A modification
of Smith's original intra-peritoneal model was described by Evans and Wells (1979a)
where after infection with P. haemolytica suspended in mucin, the multiplication
of the bacteria was measured by counting the number of bacteria in the liver of the
mouse. They obtained similar results to those found by Gilmour et al., (1979) in sheep
when testing sodium salicylate extract (SSE) vaccine ofP. haemolytica. However in the
experiment no protection was conferred against P. haemolytica serotype A2 challenge.
The reason for the enhancement of the virulence of organisms when mucin is
given to mice are not fully understood and Calver et al. (1978) in his work with N.
meningitidis has shown that the effect is due to the presence of iron in mucin. Others
suggest that there is a simple protective role as a result of the viscosity of the mucin
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suspension.
2.4 Sheep model of disease
Suitable systems to reproduce pneumonic pasteurellosis similar to the naturally
occurring disease are important in order to study the interaction between the bacterium
and the host. However, early efforts to reproduce the disease in sheep achieved only
limited success (Salisbury, 1957). P. haemolytica is carried in the respiratory tract of
high proportion of healthy sheep and in a survey into the prevalence ofP. haemolytica
in sheep Gilmour et al. (1979) isolated P. haemolytica from 95% of the sheep tonsils
and from 64% of the nasopharynges. As a result, conventionally reared sheep have
immune responses to P. haemolytica which may affect the consistent reproduction of
the disease.
Studies by Shreeve et al. (1972) have shown that lambs experience colonisation
quickly after birth probably as a result of intimate contact with their dams but this
related to passive immunity. Smith et al. (1976) have shown that antibody titres in
newborn lambs prior to suckling are generally low. Thus lambs deprived of colostrum
might be expected to give icpiodueible icsulls in challenge expeiiinenls. Gilmoui et al.
(1975) produced pneumonia indistinguishable from natural pneumonic pasteurellosis
by exposing specific pathogen free (SPF) lambs to an aerosol of P. haemolytica
serotype Al. SPF lambs are hysterectomy derived raised in microbiological secure
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facilities (Hart et al., 1971) and are free from P. haemolytica. Subsequent experiments
showed that if SPF lambs are inoculated with both parainfluenza virus type 3 (PI3) and
P. haemolytica a high proportion of consistently animals develop clinical disease.
(Sharp et al., 1978). The success of the method of Sharp et al. (1978) allowed testing
of vaccines in a controlled environment and Gilmour et al. (1979) reported successful
immunisation of SPF lambs in a series of experiments using salicylate extracts (SSE)
of P. haemolytica. Protection was demonstrated to be serotype specific, since a
challenge with a serotype not included in the vaccine was successfully potent. This
model of infection has proved useful for the study ofP. haemolytica vaccines.
2.5 Vaccines and Immunity
Vaccination is generally the accepted means of control for pasteurellosis.
Vaccines for most forms of the disease have been readily available throughout the
world. Traditionally these have been plain bacterins containing killed bacteria cells of
the particular Pasteurella species causing the disease. However the efficacy of the
current crop of commercially available vaccines are on the whole, unsatisfactory
(Gilmour, 1980 ). They do not induce good and strong immune responses required for
protection against the disease. In an attempt to obtain a more satifactory vaccine,
Gilmour et al. (1983) developed vaccines using cell extracts of serotypes Al, A6 and
A9 which conferred a considerable degree of protection on SPF lambs against
homologous, but not heterologous challenge. The results of similar vaccine experiments
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with the A2 serotypes were not succesful. These limitations have stimulated continous
research aimed at improving Pctstenrellct vaccines.
Advancement towards an effective Pasteurella vaccine, in particular against the
A2 serotype, came from the finding that solid immunity against the A2 serotype was
demonstrated when SPF lambs which had recovered from experimental pasteurellosis
caused by serotype A2 were subsequently challenged (Donachie et al., 1986). The sera
from these recovered animals contained antibodies to a number of different virulence
factors, namely OMP, IRP, leukotoxin, capsule and LPS. Subsequent serological studies
in animals recovered from pasteurellosis showed a strong antibody response to these
antigens, indicating their strong immunogenicity and their relevance as candidate
antigens for vaccines. The protective efficacy of P. haemolytica IRP vaccine has been
described by Gilmour et al. (1991). The identification and characterisation of other in
vivo antigens is strongly indicated in all Pasteurella species for the improved antigenic
composition of vaccines.
The incidence of the pneumonic pasteurellosis in Malaysia is increasing and
there is continuing need for vaccines to be used for its control (Mohamad, unpublished
1993) However, the vaccines that are available to farmers are of questionable value
(Wan Mohamad et al., 1988) and since protection of sheep by Pasteurella vaccines are
serotype-specific (Gilmour et al., 1983) there is a possibility that the differences betwen
the imported vaccine strains and the Malaysian field strains may result in this poor
efficacy. Therefore this thesis started with an epidemiological study to identify the
serotypes of P. haemolytica involved in disease and to determine their relative
prevalence in Malaysia. The findings emphasized the need for vaccine studies and
Ovipast-9-IRP was tested for its efficacy in the field. Finally the importance of
capsular antigen for a future formulation of improved Pastcurclla vaccine was also
determined.
31
CHAPTER 3.0 GENERAL MATERIALS AND METHODS
3.1 Bacterial Strains
All serotype strains of P. haemolytica used in this study were recovered from
cases of sheep pneumonia in Malaysia and from the stock strains collection at Moredun
Research Institute (MRI), Edinburgh. Scotland. These strains were subcultured into 50
ml ofNo.2 nutrient broth (Oxoid Ltd. Basingstoke, Hampshire) and grown for 18 h at
37°C without agitation after which 1 ml aliquots were put in 2 ml vials and stored at t
-70°C until required.
3.2 Culture Conditions
When required, the bacteria were removed from -70"C storage, thawed and
plated out on 7% sheep blood agar plates which were then incubated at 31X1 for 18 h.
Single colonies were picked from these plates and inoculated into 50 ml nutrient broths
which were incubated at 37"C for 18 h. If required this was used as a seed broth for
different types of culture media of larger volumes. Large quantities of bacterial cells
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for extraction were produced by inoculating 5 litre volumes ofdifferent types of broth with
50 ml of seed broth. These were incubated at 37°C for 6, 18 or 24 h depending on the
experimental requirements. For the 6 h culture the incubation was done on an orbital
shaker (LH Engineering, Stoke Poges, Bucks). Bacteria were also grown for confluent
growth on blood agar plates.
3.3 Preparation of P. haemolytica Antigens for Vaccines Trial
3.3.1 Preparation of crude Outer Membrane Protein-Polysaccharides
(OMP-PS) complex
The main steps involved in this preparation are summarised in Figure 3.1.
Preliminary purification was based on the method used by Moreno et ul. (1985) for
purifying outer membrane protein-polysaccharide complex from M meningitidis Group
B. Cells ofP. haemolytica serotype A2 in 5 litre of nutrient broth culture incubated at 37'C
for 6 h on an orbital shaker were removed by centrifugation for 1 h on an MSE coolspin
centrifuge at 2500,g (MSE, Crawley, Sussex). A 10% (w/v) solution of cetyltrimethyl
bromide (Cetavlon) in water was immediately added to the culture supernatant at room
temperature to give a final concentration of 1 % (w/v). The mixture was left for 30 min at
room temperature and the precipitate was collected by centrifugation at 10 000# for 20 min
at 4°C. The pellet was discarded and the supernatant was added to three volumes of
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absolute alcohol in an ice bath. The mixture was degassed under vacuum with swirling for
10 min and then left for 1 h at 0°C. The precipitate was collected by centrifugation at 10
OOOg for 20 min at 413, washed once in absolute alcohol and suspended in water (30 ml).
The suspension was vortexed and placed in an ultrasonic bath (Beckman, UK) for 10 min.
The mixture was centrifuged at 10 OOOg for 25 min at 4°C and the pellet was discarded.
The changes in the reactions that occur in this preparation are shown in Plate 3.1.
3.3.2 Preparation of purified OiVIP-PS complex
The crude complex was further treated as described in Figure 3.2. Briefly
the clear yellowish crude complex supernatant was chromatograhed by gel filtration on a
column (2.6 cm by 100 cm) Sepharose CL-2B (Pharmacia, Uppsala, Sweden) equilibrated
and run at 4°C with 0.1 M ammonium acetate pH 7 containing 0.01% (w/v) sodium azide.
Fractions (60 samples of 9 ml) were collected at a flow rate of 12 ml/h
and analysed for absorbance at 260 and 280 nm and for sialic acid by the resorcinol
hydrochloride method. The void volume fractions exhibiting absorbance at 280 nm and
containing sialic acid positive material were pooled. The solution was sterilised
by filtering through 0.45 and 0.22 fj.m millipore filter ( Sartorius, Germany). Lactose
Figure 3.1. Preparation of crude outer membrane protein/polysaccharide
complex of P. haemolytica A2
35
Figure 3.2. Further purification of outer membrane protein-polysaccharide
Complex of P. haemolytica A2
36
Plate 3.1. Changes in the reactions of the materials during the preparation of
capsular materials from P. haemolytica A2 by Cetavion precipitation.
Tube number
1 - Starting A2 culture supernatant
2 . Culture supernatant + cetavion (10% w/v)
3 - Cetavion pellet
4 - Cetavlon supernatant - ethanol
5 - A2 pellet in ethanol
6 - Pellet suspended in H20
7 - Crude OMP-PS complex
8 - Purified OMP-PS column fraction
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5% (w/v) was added to stabilise the purified complex and then lyophilised until required
(Tiesjema et al., 1977).
3.4 Other vaccines preparations
3.4.1 Heated whole cells
P. haemolytica serotype A2 cells grown in 250 ml nutrient broth for 6 h at
37°C were heated at 56X? for 1 h and dialysed against distilled water before lyophilisation.
3.4.2 Washed whole cells
P. haemolytica A2 cells from 250 ml nutrient broth incubated at 37"C for
6 h were harvested by centrifugation at 4200g washed once in PBS and finally resuspended
in 25 ml PBS and dialysed against distilled water for 24 h before lyophilisation.
3.5 Other vaccines used in the trials
Ovipast R : This was prepared by Hoechst, UK. It is comprised formalin-killed
whole cells ofP. haemolytica (serotypes A1, A2, A6, A7, A9 and T3, T4, T10, T15) grown
under iron-restricted conditions. Aluminium hydroxide was added to the vaccines at
0.27% (v/v) final concentration.
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Leukotoxin : Recombinant leukotoxin product. This was prepared by Dr. A.
Lianson of MRI. Briefly leukotoxin A gene from P. haemolytica A1 was expressed
in E. coli and partially purified by cell disruption and column chromatography (Lainson
et al., 1991).
Meningococcal Group B vaccine: This was kindly donated by Dr. R.Lifely
(Wellcome Biotech, Kent, UK). The vaccine is a complex of capsule polysaccharide,
outer membrane proteins and lipopolysaccharide suspended in alhydrogel. Typical
composition of complex is 48.6% sialic acid, 46.8% protein and 4.1% LPS.
3.6 Antiserum production
Rabbit: Stock rabbit sera stored at MRI were used for serotyping of
P.haemolytica. Rabbits were immunised with repeated doses of formalin-killed cells
of l\ haemolytica according to the following schedule:
A subcutaneous inoculum of 0.5 ml folllowed by intravenous doses 1 ml, 2
ml and six doses of 3 ml at intervals of three to four days were administered to the
rabbits. A trial bleed was made ten days after the last inoculation and if the titre was
satisfactory, the rabbit was exsanguinated by cardiac puncture. Sera were stored in
small aliquots at -20°C for up to 2 years.
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3.7 Serology
3.7.1 Indirect haemagglutination test (IHA)
Serotyping: P. haemolylica isolates were serotyped using a modification of the
test first described by Biberstein (1978), Fraser et al., (1982). P. liaemolytica isolates
were subcultured onto blood agar plates to check purity and to maintain the strain.
Growth from blood agar, preferably several colonies, was suspended in 1 ml of
formalised phosphate buffered saline (FPBS) (0.3% formalin) in a microcentrifuge
tube. The bacterial suspension was heated in a 56°C water bath for 30 min to release
the antigen from the cells after which bovine RBCs, fixed in 1% glutaraldehyde (Shirai
et al., 1975) were added to a final concentration of 0.5% and incubated at 37"C for 30
min. The sensitised RBCs were pelleted at 2900# and washed three times in FPBS and
then resuspended in 1 ml FPBS. One drop (0.025 ml) of each of the 16 diluted rabbit
antisera was dispensed into U-bottom microtitre plates (Cookes Engineering Company,
Alexandria, Virginia, USA). After addition of 0.025ml of sensitised RBCs suspensions
to the appropriate wells the plate was left at room temperature for 2 h or overnight
before examination for haemagglutination. A positive result was indicated by an even
mat of RBCs over the bottom of the well, while negative results were indicated by a
small button ofRBCs in the centre of the well.
40
3.7.1.1 Measurement of antigen
The samples to be tested were diluted in FPBS in ten fold dilution from 1 in 10
to 1 in 100,000 in 2 ml volumes. Glutaraldehyde fixed RBCs were sensitised by adding
to the sample 0.2 ml of a 5% washed suspension of RBCs. Cells were washed as
described above then added in 0.025 ml volumes to microtitre plate wells in duplicate.
Equal volumes of positive or negative control sera were then added and the highest
dilution of sample which produced haemagglutination was the IIIA titre of the sample.
3.7.1.2 Measurement of antibody
Antibodies against 1'. haemolytica were measured by testing serum
samples by the IHA method described by Shreeve et a/., (1972) and modified by Fraser
et a/., (1983).
3.7.2 Enzyme-linked immunosorbent assay (ELISA)
The technique used was basically that described by Burrells et al. 1979).
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3.7.2.1 Indirect ELISA for detecting 35 kDa antibody
The antigen, P. haemolytica A2 35 kDa IRP prepared by affinity
chromatography, was diluted in carbonate/bicarbonate buffer, pH 9.6, to give a final
concentration of 200 ng/ml and added in 100 /x\ volumes to wells in a microtitre plate
(Dynatech 129A, Laboratories Ltd. Billinghurst, Sussex). The plates were incubated
at 4°C overnight. Plates were then washed three times with PBS containing 0.05%
Tween 20 (PBS/Tween). Horse serum (20%) was used to avoid non specific adsorbtion.
Standard and test sera were added to 100 /u.1 volumes to the wells and incubated at 4"C
overnight. The standard positive convalescent sera was titrated at 1/50-1/6400 dilutions,
while the negative and test sera were used at a dilution of 1/50. Serum dilutions were
removed from the wells, the plates washed three times with PBS/Tween and 100 /./I of
donkey anti-sheep IgG conjugated with horse-radish peroxidase (HRP) diluted 1/200
in PBS/Tween added to the wells. After incubation for 1 h at 37"C the plates were
emptied and washed. Enzyme substrate {orthophenylamine diamine (OPD), Sigma
Chemical Co., Poole, Dorset} at a concentration of 0.04% in citrate phosphate buffer
pi I 5 was added to the plates in 100 jj.I volumes. After 5 min at room temperature the
reaction was stopped by addition of 50 /u\ of 2.3 M sulphuric acid. Results were
recorded as optical densities at 492 nm (OD,t92) and were determined using a
multichannel spectrophotometer (Dynatech 5000).
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3.7.2.2 Sandwich ELISA for detecting anti-Al capsule antibodies
Flat bottomed micro-ELISA plates were coated with a 1/100 dilution of anti-
A1 capsule monoclonal antibody (7/13) (Wilson et al., 1991) at 37°C overnight. Plates
were then washed and 50% horse serum in PBS was added as a blocking step and
incubated for 1 h at 37°C. The plates were washed three times with PBS/Tween and Al
capsular antigen at 1/50 dilution in PBS/Tween were added to wells and incubated for 90
min at 37°C. The capsular antigen was prepared by heating 1 litre of 18 h culture at 56"C
for I h. Cells were removed by centrifugation and filtration before lyophylisation. Before
using the freeze dried material was re-suspended in 4% of the original volume. The
remaining steps are as described in section 3.7.2.1.
3.7.2.3 ELISA to detect P. haemolytica A2 OiVIP antibodies
The OMP were prepared as described by Donachie & Gihnour (1988).
Briefly, washed cells were sonicated in an MSB sonicator (150 watt, MK2) for three pulses
at maximum power with intermittent cooling. The sonicate was then centrifuged at 4000#
and the supernatant fluid centrifuged at 30,000# for 1 h to pellet envelopes. The envelopes
were re-suspended in PBS with 2 % Sarkosyl (w/v), incubated at 37"C for 1 h and then
centrifuged at 4"C at 100,000#. The pellet was resuspended in 0.01M TR1S. This OMP
diluted in carbonate/bicarbonate buffer of pH 9.6 was used to coat the micro-ELISA
plates. The remaining steps of the ELISA were as described above for 35
kDa 1RP ELISA.
3.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
A discontinuous system employing slabs of gel 1.5 mm thick with a 12% (w/v)
separating gel and a 4% stacking gel and the buffer system of Laemli (1970) was used.
Samples were diluted 1:1 with sample buffer containing 2% (w/v) SDS and 4% (v/v)
2-mercaptoethanol and boiled for 5 min before application to the gels. The gel was run
for approximately 6 h with the voltage set at 350 volts. Proteins were detected by
Coomassie-blue or silver staining. LPS was detected by the silver staining method of
Tsai & Frash(1982).
3.9 Western blotting
The method of Burnette (1981) as modified by Sharp & Herring (1983) was
used. Electrophoretically resolved proteins were transferred on to nitrocellulose paper
(pore size 0.45 /^m, Sartorius) at 0.1 I A for 6 h or overnight at RT. The nitrocellulose
sheet was stained with Ponceau red for 30 sec at room temperature to make sure the
protein had been successfully transferred onto nitrocellulose. The sheet was then
immersed in horse serum in an equal volume of blot wash buffer {BWB, PBS with
0.5M NaCl, 0.5M 0.001 M-EDTA and 0.5% (v/v) Tween 20} and shaken on an orbital
shaker for 1 h at 37X2. The fluid was discarded and replaced with horse serum in BVVB
(1:9 v/v) containing the serum (2.5% v/v) to be tested. When different sera were to be
tested the nitrocellulose sheet was cut into 5mm strips and placed in a blotting tray
(BioRad). Two millilitres of diluted test sera were added to each well. Positive and
negative controls were also included. After incubation at 37°C for 1 h, the sheet was
washed in BWB. Subsequently, the sheets were incubated with horse-radish peroxidase
(HRP) conjugated anti-mouse or anti-sheep Ig (Sigma or Scottish Antibody Production
Unit (SAPU) } and then again extensively washed as before. Colour development was
carried out at room temperature in 0.1M Tris buffered saline (TBS) (pH 7.6) containing
diaminobenzidine (DAB) at 0.5 mg/ml and 2 /J of30% (v/v)Hp2 The sheets were washed
in tap water to stop any further enzyme substrate reaction. The immunoblots were dried
and analysed for antibody/antigen reactions.
3.10 Dot blotting
The dot blot apparatus manufactured by Millipore, UK was used. Nitrocellulose
paper was set in the apparatus and the test antigens added to the wells and left to bind for
1 h at 37"C. The nitrocellulose sheet was then removed and the whole sheet blocked with
20% horse serum. The sheet was then exposed to appropriate antisera in 5% Marvel
(Primary Beverages, Stafford, UK) in PBS. After incubation at 37'C for 1 h the sheet was
washed in BWB. Sheep anti-mouse IgG conjugated to HRP (SAPU) (1:200 in BWB)
was added and incubation carried out for 1 h at 37°C. After washing, the substrate
solution {(5mg DAB in 20 ml of Tris pH 7.4) in 50 /d H202} was added until
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colour developed. The reaction was stopped with distilled water and the blot was analysed.
3.11 Chemical analysis
3.11.1 Protein
Protein in the test sample was detected and measured by the techniques and
procedure described in the Pierce BCA Protein Assay Method. Briefly 200 /J working
reagent (Pierce BCA Protein Assay Reagent) was dispensed into wells ofmicrotitre plates.
After the addition of 25 ^1 ofeach standard or unknown protein sample into each well the
plate was incubated for 30 min at 37°C. The plates were cooled to room temperature and
the absorbance at 562 nm was measured. The protein concentration of the sample was
calculated using a prepared standard curve.
3.11.2 Sialic acid
Quantitative determination of sialic acids was achieved by the method of
Svennerholm (1979). Briefly the reagent was added to test samples and the tubes heated
for 15 min in boiling water bath. The tubes were cooled and amyl alcohol added. The
absorbance at 450 and 580 m/i were read against pure amyl alcohol as blank using a
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Beckman Spectrophotometer. The amount of sialic acid was calculated using a prepared
standard curve.
3.11.3 Lipopolysaccharides (LPS)
LPS content was determined by the kinetic turbidimetric assay method using
Limulus Amoebocyte Lysate (LAL) as described by Harris et al. (1983).
Sequential readings at absorbance of 380 nm, were taken on an IL Monarch Centrifugal
Analyser.
3.12 Experimental animal techniques
Mice: Mice used in experiments were C57 black strain, bred at the MRI. The mice
were of both sexes and were 6-8 weeks old at the start of the experiment.
Inoculations : Intraperitoneal (i.p.) injections into mice were given without
anaesthesia. Mice were injected into the abdomen slightly to the left of the umbilicus using
a 25 gauge needle.
Mouse model of P. haemolytica infection: The model described by Evans and
Wells (1979a) was adopted. Groups ofmice were inoculated i.p. with at least 2 LD50of the
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P. haemolytica isolate required in hog gastric mucin (ICN Pharmaceuticals). After 6 h the
mice were killed by cervical dislocation and the livers removed aseptically. These were
then individually macerated with 9 ml of peptone water (Oxoid) in a Colworth stomacher
(Seward, London). Serial ten-fold dilution in peptone water were plated out for counting
of viable cells by the method ofMiles et al. (1938). The mean viable count and standard
errors of the means each group was calculated and expressed as log,0.
3.13 Vaccines formulation
Antigen and vaccine used were resuspended in distilled water to the required
dosage concentration. Aluminium hydroxide (Alhydrogel, Superfos Denmark) was added
to all vaccines to a 0.27% (v/v) final concentration.
Vaccination and challenge of mice: Ten mice of various groups were each given
two doses of 0.1 ml of vaccine intraperitoneally with 14 days between the two
inoculations. Fourteen days after the second inoculation, these mice and a group of
uninoculated control mice, were challenged i.p. as described in the mouse infection model.
After 6 h the mice were killed and viable counts performed on the whole liver suspension.
Vaccination and challenge of sheep: Three groups of4 lambs aged 3 months and
3 groups of ewes aged 2 years were used in this experiment. The sheep had been clinically
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healthy and tested negative for Pasteurella spp. The ewes and the lambs were randomly
allocated according to vaccines group. Two vaccine preparations consisting of crude and
purified OMP-PS vaccines complex were administered to two groups in each age group.
The animals were vaccinated subcutaneously (2ml dose) on the lateral aspect of the middle
third of the neck at day 0 and booster given 4 weeks later. The remaining group in each
group were sham-vaccinated and served as controls. The animals were grazed together at
pasture raised at Moredun farm for the duration of the experiment.
3.14 Statistical analysis
Where possible, t test were performed and means and SE were calculated. Where
the data were unsuitable, the Mann-Whitney Ranking Test (Snedecor & Cochrane, 1987)
was used to determine the significant differences between group data.
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CHAPTER 4.0 EPIDEMIOLOGICAL STUDIES ON PASTEURELLA
HAEMOLYTICA IN MALAYSIAN SHEEP AND GOATS
4.1 Serotyping of Malaysian P. haemolytica isolates
4.1.1 Introduction
An epidemiological study of pasteurellosis in Malaysian sheep and
goats is required to identify the serotypes of P. haemolytica involved in disease and
determine their relative prevalence. This information can then be used to develop
relevant control programmes involving management and disease prevention
methods. As immunity to P. haemolytica infections is believed to be serotype specific
this type of study should also help identify the serotypes to be included in vaccines.
There have been no reports on the prevalence of different serotypes in
the country and the first study was initiated in 1989 where strains of P. haemolytica
were sent to the Moredun Research Institute (MRI) for serotyping. The purpose of
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this study was to to determine the range of serotypes isolated during the year 1989-
1993 from sheep and goats inMalaysia.
4.1.2 Materials and Methods
The strains submitted were isolated at Malaysian Agriculture Research
and Development Institute (MARDI), University Pertanian Malaysia, the Regional
Diagnostic Laboratory and the Veterinary Research Institute from sheep and goats
throughout Malaysia, which were either clinically abnormal or had a pathological
condition at post mortem (see map in Appendix I).
Strains were received on blood agar plates or slopes or freeze-dried
and were serotyped either directly from the original culture or after subculture on 5%
sheep blood agar. Strains were serotyped by the rapid IHA test as described in the
general Materials and Methods of this thesis.
4.1.3 Results
A total of 437 P. haemolytica strains was submitted for serotyping (320
isolates from sheep and 117 from goats) and 364 typable (287 from sheep and 77 from
goats) and 73 untypable (33 from sheep and 40 from goats) strains were isolated. The
majority of sheep and goats isolates were from lambs and kids (73% and 71%
respectively). The P. haemolytica isolates in these animals were primarily associated
with pneumonia in adult animals and septicaemia in the young. The predominant
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serotypes were A2, Al, A9 and A7 (38.2%, 13.7%, 13% and 10.1% respectively). Six A
serotypes (A5, A6, A8, All, A12 and A13) were isolated in smaller numbers. The
isolates of biotype T was very rare and only serotype T3 (2.5%) was isolated (Table
4.1). The serotype distribution pattern is quite similar for both sheep and goats.
The clinical disease condition from which P. haemolytica strains were derived
and the main pathological conditions diagnosed are shown in Tables A & B in the
Apppendix II. The organ from which P. haemolytica strains were isolated are shown in
Table C. Complete clinical and pathological data for the cases suspected of
pasteurellosis submitted to the various regional diagnostic laboratories were not
available for all the laboratories. In post mortem examinations of animals only lungs
and lymph nodes were normally examined and cultured for the bacterial isolation. In
this study eighty percent (351/437) of the strains were isolated from lungs. Recovery
of the organisms from nasal swabs was very poor (only 25 cultured out of 124
samples submitted). P. haemolytica were also recovered from the other organs but
only account for 14 % (61/437) of the total strains isolated.
Histopathological examination was performed on lungs from majority of
sheep and goats cases. P. haemolytica strains were associated mainly with fibrinous
pneumonia and bronchopneumonia. The complete histopathological data were only
available from two centres in Petaling Jaya and University Pertanian Malaysia
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laboratories. Untypable strains comprised 16.7% of the isolates. Proportionally there
was a higher incidence of these strains in goats (54.8%) than in sheep (45.2%). Other
bacteria were also isolated from 25% (108/437) of the animals from which P.
haemolytica strains were also isolated. From pneumonic lungs P. multocida,
Haemophilus somnus and Actinobacillus spp. were isolated. Clostridium spp., Salmonella
spp., E. coli and Listeria monocytogenes were recovered from septicaemic cases.
Table 4.1. The prevalance of serotypes of P. haemolytica isolated from sheep
and goats pasteurellosis in Malaysia during 1989-1993.
Serotypes 1989* 1990 1991 1992 1993 1989-93 Nos
A1 7 11.5 28 11 11.5 13.7 60
A2 14 36.5 55 44.5 38 38.2 167
A5 7 0 0 2 0 1.8 8
A6 7 0 0 2 1 2 9
A7 11 14.5 8 11 7 10.1 44
A8 0 0 0 1 3 0.8 3
A9 36 7.5 0 14 8 13 57
All 0 2.5 0 0 0.5 0.6 2
A12 0 0 0 1 1.5 0.5 2
A13 0 0 0 0 1 0.2 1
T3 7 0 0 2 3.5 2.5 11
UT 11 27.5 9 11.5 25 16.7 73
Total Nos
n-i i
80 50 85 112 110 437
"■-Expressed as a percentage of the total number of strains exami:
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4.1.4 Discussion
Not all laboratories record diagnoses in the same manner so some
interpretation had to be applied in order to summarise the information. Nevertheless,
the P. haemolytica isolates recorded in this study are considered to be a representative
sample of the prevalence of this organism in the small ruminant population in
Malaysia. Although complete clinical and pathological data for the disease were not
available for all the laboratories, the majority of the cases had undergone post mortem
examination and gross pathology and histopathology results were available for most of
the cases and can be regarded as conclusive of pasteurellosis. A small number of
isolates were from nasal swabs and the problem of poor isolation and sample
contamination were unavoidable. The application of long swabs to disinfected nasal
region partly solved the problem.
The primary diseases associated with P. haemolytica were pneumonia
in adult sheep and goats and septicaemia in the young, as has been extensively recorded
elsewhere (Gilmour et al., 1980). The serotypes isolated from these conditions also
largely agree with the recognised pattern in sheep (Gilmour & Gilmour, 1989) with
serotype A2 being the most important pneumonic isolate in sheep and goats. However,
T biotypes were rare in Malaysian isolates probably because they are associated with
temperate climate animals (Gilmour & Gilmour, 1989). Of the 437 isolates of P.
haemolytica typed 16.7% were untypable. Similar to results of this was recorded by
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Biberstein and Thompson (1976) where 12% and 28% of nasal isolates were untypable
in two surveys and Ball et al. (1993) reported that 18% of their isolates were
untypable.
The present study indicate that the serotype distribution for the A serotypes is
quite similar and not significantly different (PX3.05) to a survey of ovine pasteurellosis
cases at MRI during 1982-1993 (Table 4.2) (Quirie, 1994, unpublished data) and in
Northern Ireland (Ball et al., 1993), indicating little variation in this distribution in
Malaysia.
These results may be of significance in the formulation of vaccines against
ovine and caprine pasteurellosis in Malaysia, as they give an indication of the serotypes
most commonly found in pneumonic cases in the field.
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4.2 OMP and LPS profiles of Malaysian and United Kingdom strains - a
comparison
4.2.1 Introduction
Ovine pneumonic pasteurellosis has caused serious economic loss to the
farming industry of Malaysia and the United Kingdom. In Malaysia the disease remains
a very serious problem accounting for more than 50% of sheep and goats mortalities
despite the use of vaccines. The vaccines commonly used in Malaysia are imported from
the UK and although they contain the common important serotypes, much poorer efficacy
was experienced in Malaysian farms (Wan Mohamad el a/., 1988). From the above
serotyping studies it was shown that the serotype distribution of P. haemolytica for the A
biotype strains for Malaysia and the United Kingdom are quite similar. It is possible that
the differences which might be present between the serotypes from both countries possibly
contribute to this poor protection of the animals.
There are 17 immunologically distinct serotypes of P. haemolytica.
Vaccination with one serotype does not confer protection on animals against challenge
with another serotype (Gilmour el ai, 1983). In addition, antigenic differences within the
serotypes may be such that vaccination with one strain may not give complete protection
against another strain of the same type (Donachie, personal communication). More recently
the ELISA has been used for studying antigenic relationships and vaccine strain selection
among pathogenic organisms. Differences between strains have also been shown by non-
serological methods. Analysis of outer membrane protein (OMP) and lipopolysaccharide
(LPS) profiles has been used for examining strain variation within species of bacterial
pathogens. Typing scheme based on OMP and LPS profiles in SDS-PAGE have been
developed and used for epidemiologiacal studies in both human and veterinary pathogens
(Loeb and Smith, 1980; Lugtenberg et al., 1984; Ali et al., 1992). The combined analysis
of both OMP and LPS profiles by SDS-PAGE has also been carried out for E. coli
( Achtman and Plushchke, 1986) and P. multocida ( Lugtenberg et al., 1984).
The OMP and LPS ofP. haemolytica have not been studied widely. Little
is known about variation ofOMP and LPS within the species particularly within biotype
A strains. Although the LPS from different serotypes is known to be antigenically related
( Donachie et al., 1984b; Durham et al., 1988)), major differences occur in the LPS
associated with A and T biotypes. Adlam, (1989) reported strains belonging to A biotypes
have a characteristic rough-type LPS whereas T biotypes are of smooth-type. When
analysed by SDS-PAGE and silver staining, smooth-type LPS is separated into low
molecular mass fraction, consisting of the lipid A-oligosaccharide core region and a
distinctive ladder pattern of high molecular mass bands while the rough LPS consisting
only of the core oligosaccharide lipd A visualised as a number of low molecular mass
bands only (Hitchcock et al., 1986).
The present study was conducted to examine and compare the OMP and
LPS profiles of a selection of common serotypes of P. haemolytica isolates obtained from
sheep pneumonia in the UK and Malaysia, with the aim of identifying similarities and
differences within the serotypes which could be of epidemiological significance or prove
useful to formulate more effective field vaccines.
4.2.2 Materials and methods
Bacterial strains: Twenty four isolates of P. haemo/ytica common to UK
and Malaysia were examined in the present study. The isolates comprised of 6 each of
serotype Al, A2 A7 and A9 including four from healthy sheep and the remainder from
pneumonic cases of sheep and goats. Isolates from healthy sheep were obtained from the
nasopharynx whereas those from pneumonic animals were obtained from the lung lesions.
The isolates from Malaysia were obtained from the farms mentioned earlier
in Chapter 4 and were made over a three year period (1990-93). The UK isolates were
obtained from the reference stock strains collections at Moredun Research Institute. The
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Table 4.3. Pasteure/la haemolytica strains examined in the study
Source of strains
Strain . Serotype Origin Host species Site of isolation
M 954/89 A1 Malaysia Ovine Pneumonic lung
M/M 1.2/92 A1 Malaysia Ovine Nasal cavity (healthy)
M/'M 1.3/92 A1 Malaysia Caprine Pneumonic lung
M/M 2.1/92 A2 Malaysia Ovine Nasal cavity (healthy)
M 945/89 A2 Malaysia Ovine Pneumonic lung
M/M 2.2/92 A2 Malaysia Caprine Pneumonic lung
M/M 7.1/92 A7 Malaysia Caprine Pneumonic lung
M 927/89 A7 Malaysia Ovine Pneumonic lung
M/M 7.2/92 . A7 Malaysia Ovine Nasal cavity(heallhy)
M/M 9.1/92 A9 Malaysia Caprine Pneumonic lung
M/M 9.2/92 A9 Malaysia Ovine Nasal cavity (healthy)
M 933/89 A9 Malaysia Caprine Pneumonic lung
H 379 A1 UK Ovine Pneumonic lung
DO 151 A1 UK Ovine Pneumonic lung
HI 83 A1 UK Ovine Pneumonic lung
EO 200 A2 UK Ovine Pneumonic lung
DO 152 A2 UK . Ovine Pneumonic lung
DO 689 A2 UK Ovine Pneumonic lung
DO 123 A7 UK Ovine Pneumonic lung
H 35 A7 UK Ovine Pneumonic lung
H 36 A7 UK Ovine Pneumonic lung
DO 148 A9 UK Ovine Pneumonic lung
H 49 A9 UK Ovine Pneumonic lung
11 I 85/6 A9 " UK Ovine Pneumonic lung
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details are shown in Table 4.3. After primary isolation, the isolates were stored in nutrient
broth No. 2 (Gibco) at -70°C and were routinely subcultured on blood agar (Oxoid)
containing 5% sheep blood at 37°C.
Preparation ofwhole cells, envelopes and OMP: Bacterial whole cells,
envelopes and OMP were prepared as described by Donachie & Gilmour (1988). When
required 50 ml seed cultures were intiated in nutrient broth (Gibco No.2) and six hours
later inoculated into 1 litre volume. Cells were grown at 37"C overnight, then harvested
by centrifugation and washed twice in PBS (0.01 M-sodium phosphate, 0.15M-NaCl, pH
7.4). Bacterial suspensions were adjusted to give protein concentration of 1.5 mg ml"1 as
determined by Pierce BCA Protein Assay Reagent. The washed cells were sonicated in an
MSE sonicator (150 watt, MK2) for 30 second pulses at maximum power with intermittent
cooling. The sonicate was then centrifuged at 40 000 g and the supernatant fluid
centrifuged at 30 000 g for 1 h to pellet envelopes. Envelopes were suspended in 0.1 M
Tris/HCl, pH 7.4. The pellet was then resuspended in 4 ml PBS and Sarkosyl (2% w/v)
was added. The suspension was incubated at 37^ for 1 h and harvested by centrifugation
at 100 00Og for 1 h. The OMP pellet was resuspended in 50 1 Tris/HCl (0. IM, pH7.4)
before storage at 20"C.
Preparation of LPS: LPS was obtained by a modified method as
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described by Donachie (1984a). Briefly bacterial colonies from an agar plate were taken
and suspended in 45% aqueous phenol in a microcentrifuge tube. The suspension was
agitated vigorously for 10 min then cooled on ice at 4°C for 30 min. followed by
centrifugation at 3500 g for 10 min. The top layer which contained the LPS was removed
and loaded directly in the gels.
SDS-PAGE: P. haemolyiica proteins were separated by SDS-PAGE, using





The results of PAGE are shown in Figure 4.1 and Figure 4.2. The OMP
profiles of strains from UK and Malaysia show no distinct differences. Different isolates
of the same serotypes had similar polypeptide profiles (Fig. 4.1 Lane 2-9). The reference
A2 strain from UK and field A2 strain from Malaysia showed slight differences in
migration of structural polypeptides (Fig.4.1, Lane 4 and 5). The patterns for the other






45 -♦ <-42 kDa
Figure 4.1. SDS- PAGE ofwhole cells proteins P. liaemolytica serotypes Al, A2,
A7, A9 common to Malaysia ( Lane 2, 4, 6 and 8) and the UK
(Lane 3, 5, 7 and 9). Molecular mass markers are shown in lane 1.
Each lane contained approx. 20 /ug of protein.
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Figure 4.2. SDS- PAGE of envelope proteins P. haemolytica serotypes Al, A2,
A7, A9 common to Malaysia ( Lane 2, 4, 6 and 8) and the UK
(Lane 3, 5, 7 and 9). Molecular mass markers are shown in lane 1.
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Figure 4.3. SDS-PAGE of P. haemolytica LPS of serotypes Al, A2 and A7
common to Malaysia ( Lane 2, 4 and 6) and the I K (Lane 3, 5 and
7). The LPS obtained bv rapid aqueous-phenol method and silver-
stained. They are of the rough type 3 LPS.
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The OMP profiles in Coomassie-blue-stained gels, cifserotype A2 from both
locations were very similar and consisted of five major proteins and approximately 17-21
minor proteins. The profiles of the serotype Al, A7 and A9 from both locations were
similar. The OMP fractions which could be assumed as major proteins are of apparent
molecular masses of 29,39,40 and 42 kDa.
The LPS profiles
In the present study, the LPS profiles of 18 isolates of P. haemolytica from
both countries comprising of serotypes A1, A2 and A7 were examined. Analysis of LPS
revealed 3 distinct profiles among the A biotype. Representative examples of these LPS
profiles are shown in Figure 4.3. It was noted that the resolution of the high molecular
mass region is poor. The LPS pattern among the serotypes Al and A7 appeared to be
identical and do not have as many bands as the ladder-patterns of the smooth-type LPS of
the T biotype (results not shown). Comparison of the LPS patterns of the A2 strains from
UK and Malaysia showed a difference at 18 kDa region but both are rough types.
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4.2.4 Discussion
The objective of this study was to examine and compare the OMP and LPS
profiles of a selection of common P. haemolytica isolates obtained from Malaysian and
UK sheep farms. The aim was to detect any differences which could be useful in
epidemiological studies and later help in the formulation of universal vaccines. The OMP
profiles of24 isolates examined in the SDS-PAGE gels were similar to those described in
a previous study of the same A serotypes from UK isolates (Murrray, 1992, unpublished
data).
"t he reference and the field isolates strain's from' the two countries showed
slight differences in migration of structural polypeptides but were generally very similar.
The field strains showed a gel profile in which all the major polypeptides migrated quite
similarly to all of the reference strains used in the study. This findings are in agreement
with Knights et al. (1990) who showed that considerable qualitative similarities were noted
within the A biotype isolates.
The OMP profiles comprised of four major proteins with apparent
molecular masses of 29, 39, 40 and 42 kDa and between 17-21 minor proteins. This
findings are with agreement with that of Davies et al. (1992) who compares the OMP
profiles of2 isolates of serotype A1 demonstrated that four to five major proteins with at
least twenty minor proteins were present. The authors also suggested that the molecular
masses of the major proteins are located within the same molecular mass range desribed.
The results also confimed that obtained by Squire et al. (1984) who
separated two major proteins of molecular masses 30 and 42 kDa in the OM-enriched
fraction. Knights et al. (1990) proposed that polypeptide bands ofmolecular weights 4, 7,
9, 15, 16, 22, 23, 30, 33, 41,42, 43 and 44 kDa appeared to be located in the outer
membrane.
The rough type oTLPS based on SDS-PAUL profiles of biotype A strains
in this study confirm the findings ofAdlam (1989) and are of LPS type 3 (Ali et al., 1992).
According to Ali et al. (1992) LPS type 1 and type 2 were both smooth-type LPS with
apparently identical O-antigen side-chains but with different core oligosaccharide region.
LPS type 3 was rough, but not possessing O-antigen side chain, but its core-oligosaccharide
region was similar, although not identical to that of type 1 LPS. However, Davies et al.
(1992) demonstrated that most of the serotype Al isolates that he examined possesed a
high molecular mass ladder pattern in silver-stained SDS-PAGE gels characteristic of
smooth-type LPS. These were designated as type 1. It has been suggested that the
resulting LPS profiles were affected by the staining and extraction procedure of the LPS.
However, he demonstrated that the majority of serotype A2 isolates possesed LPS of type
3 whereas the remaining A2 isolates had a unique rough LPS type; types 4 and 5. The
authors also suggested that rough type LPS types, and type 3 LPS in particular, are
primarily associated with acute pneumonia in sheep whereas smooth LPS of type 1 is
associated with acute pneumonia in cattle. This findings appeared to agree with our results
since majority of the isolates examined were of rough type 3 LPS and they were obtained
from cases of sheep and goat pneumonia.
The epidemiological significance of OMP and LPS migration patterns
obtained by SDS-PAGE was summarised above and more fully discussed elsewhere
(Davies et al., 1994). This is the first study comparing variation in the OMP and LPS
patterns of selected P. haemolytica strains common to two countries and may be useful
in epidemiological studies.
However, using PAGE alone, any assumption that the isolates are different
would be erroneous. Attempts to correlate polypeptide migration patterns with antigenic
variation among pathogenic organisms by using blots with limited range of antisera
showed that strains with identical polypeptide patterns can react differently (Harris et al.,
1979). While PAGE is an extremely powerful epidemiological tool, it is limited by
inability to predict antigenicity, crucial in determining vaccine strategy.
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CHAPTER 5.0 ASSESSMENT OF EFFICACY OF A NEW
P. HAEMOLYTICA IRON-REGULATED
PROTEINS (Ovipast-9-IRPR, HOECHST, UK)
VACCINE IN MALAYSIAN SHEEP FLOCKS
5.1 Evaluation ofOvipast-SMRP1* vaccine against natural pneumonic challenge
in sheep
5.1.1 Introduction
The results ofepidemiological studies on the prevalence ofP. hciemolyticci
in Malaysia and the UK, described in Chapter 4.0 showed no real difference between
the strains suggesting that vaccines containing the British strains can be used in trials
in Malysian sheep flocks. Work at MRI, has shown that IRPs produced by P.
haemolytica cells when growing in infected hosts stimulate a strong antibody response
(Donachie etal., 1988). These IRPs can be induced to grow in vitro by removal of iron
from the media and their inclusion in vaccines in sheep enhances the protective efficacy
of these vaccines against P. haemolytica challenge (Gilmour et al., 1991).
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Pasteurellosis of sheep is reportedly best prevented by multivalent
vaccines, since there is no cross-protection is not evident between serotypes (Gilmour
et al., 1979, 1983). However, the efficacy of these vaccines is difficult to evaluate
without recourse to experimental challenge (Sharp et al., 1978). Existing serological
methods have not proved suitable for detecting protective serum antibody responses to
individual serotypes. The IHA test is highly specific for capsule polysaccharide antigen,
but is insufficiently sensitive, while ELISA based on SSE extract antigen (capsule
polysaccharide, protein, LPS) detects cross-reacting antibodies (Burrells et al., 1979).
Variouspasteiirella antigens have been employed in ELISA including SSE
(Burrells et al., 1979), phenol water extract (Donachie et al., 1984a), saline extract
(Confer et al., 1985), LPS (Confer et al., 1986) formalised cells (Opuda-Asibo et al.,
1986) and cytotoxin (Mosier et al., 1986). These preparations were used to measure
antibodies against experimental single serotype vaccines. Cross-reactions between
serotypes occur with crude antigens such as SSE (Donachie et al., 1983) and with more
defined preparation such as phenol water extract and LPS (Donachie et al., 1984b,
Confer et al., 1986).
This study was conducted to determine the relative value of the new
vaccine containing iron-regulated proteins (Ovipast-9-IRPR, Hoechst, UK) in the control
of pasteurellosis under natural conditions using serological monitoring. IHA test and
ELISAs were used to quantify antibody responses against relevant specific antigens. The
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incidence ofdisease and the serological changes in these treated groups were compared
with those in control untreated groups of animals from the same farms over the same
periods.
5.1.2 Materials and Methods
Vaccines study design: For the purpose of this study, arrangements were
made with a number of sheep farms of various flock sizes, whereby 1000 animals could
be suitably treated and identified. Four farms were choosen for detailed field study based
on their willingness to co-operate and their close location to MARDI. Farm A and Farm
B were medium sized farms with 500-2000 heads of animals. They were situated at
MARDI stations at Serdang and Kluang. Farm C belong to a private company,
Kumpulan Guthrie which has a total sheep population of 10,000 heads raised under oil
palm plantations. Farm D belong to a smallholder farmer who owned 200 heads of sheep
(see Appendix 1). The flock comprised of local sheep (Malin) and cross-bred (Dorset-
Malin) and normally were allowed to graze under oil palm or rubber areas between 7
am to 4 pm. They were housed during the night in platform houses made ofwood.
These animals were to receive no special care and were to be treated in the
same manner as all other animals in the farms. The study commenced in November 1992
and ended in October, 1993. During this period, 750 animals were vaccinated with
Ovipast--9-IRPR vaccine and 250 animals were identified as control unvaccinated
animals. The ewes, their offspring and the rams were included in this study. The farm
managers identified each animal at birth with an ear tag and maintained lambing and
individual treatment records for the occurence ofpneumonia.
At the start of the study, a serological profile of the flock was establised
by testing several groups ofsheep including ewes, rams, weaning lambs and growers of
various ages.
The vaccines were administered in the dosage recommended by the
manufacturer (2 ml/animal given subcutaneously). Animals in the vaccinated groups
received two vaccinations 28 days apart.
Immediately prior to vaccination, blood samples were collected from 20
per cent of the trial groups. In some of the farms the blood samples were collected
weekly for 8 weeks, but in others only 5 collections were made, at days 0, 1 week, 3 5
weeks and 7 weeks post-vaccination. All sheep that died were sent to the regional
diagnostic laboratory for autopsies.
Serological Methods: Sera were analysed for IHA antibody and for
specific antibody to 35 kDa IRP antigen and anti-Al capsule using ELISA, as described
in the general Materials and Methods.
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5.1.3 Results
The mean serum antibody responses to each of these antigens of the
vaccinated and control groups plotted against times for the farm A, farm B, farm C and
farm D are shown in Fig. 5.1a-5.1d, Fig. 5.2a-5.2d, Fig. 5.3a-5.3d and Fig. 5.4a-5.4d
respectively. There were significant differences (p<0.05) in the antibody responses
between vaccinates and controls at various post-vaccination time intervals for IHA
antibody, 35kDa and anti-Al capsule antigens ofP. hciemolytica in all the trial farms.
Prevalence of IHA antibody in the flock: At the start of the study, the
prevalence of the IHA antibodies in the vaccinated flock in all four sheep farms was not
significantly different (p>0.05) compared with control unvaccinated flocks (Fig. 5.1a-
5. Id). The mean EHA antibody titres of the vaccinated animals in all the farms
significantly increased shortly after administration of the IRP vaccines from mean titres
of 1:4 at the start of the study to 1:64 one week after vaccination. There was no
significant change in the mean titres of IHA antibody in the control animals throughout
the study period.
One week after adminitration of the vaccines there were significant
differences (P<0.05) in mean IHA antibody titres between vaccinated and unvaccinated
groups. The vaccinated group's mean antibody titre was significantly greater than the
mean titre of the unvaccinated control at weeks 1, 3 and 5. The mean pre-vaccination
IHA titres at days 0 were low (1:4). After the first injection the mean titre of the animals
had increased by day 7 to 1:64, then decreased until day 21 and increased significantly
after booster to level >1:128 and thereafter. The mean titre of the unvaccinated control
remained low from days 0 to 35.
The presence of 35 kDa antibody: There were significant differences in
3 5 kDa IRP antigen mean optical density readings (OD492) between vaccinated and
unvaccinated groups in all the farms. The mean OD readings for the vaccinated group
was significantly greater than the mean OD for the unvaccinated group at 1 week, 3
weeks, 5 weeks and 7 weeks post-vaccinations (p<0.05). The mean OD readings of the
vaccinated group increased from OD 0.45 on day 0 to OD 0.98 on day 7, but decreased
sharply thereafter and increased again after a second vaccination on day 35 and remained
unchanged thereafter. Its OD readings reached maximum 7 days after second injection.
The sera from the unvaccinated control group on day 0 showed mean OD readings of
0.4 because more than half of the animals had high passive antibody levels. This groups
mean OD decreased to OD of 0.3 on day 35.
The presence of anti-Al capsular antibody: There were significant
differences in anti-Al capsular mean OD readings (P<0.05) between vaccinated and non-
vaccinated groups in all the farms. The mean OD for the vaccinated group was
significantly greater than the mean OD for the unvaccinated group on weeks 1, 3 and
5. The mean OD readings on days 7 was 1.1. The mean OD reached a maximum 7 days
Fig. 5.1a. Mean IIIA antibody response to P. haemolytica antigens in sheep
vaccinated with Ovipast-9-IRP vaccine
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Fig. 5.1b. Mean IIIA antibody response to P. haemolytica antigens in
sheep vaccinated with Ovipast-9-IRP vaccine
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Time post-vaccination (weeks)
Fig. 5.1c. Mean IIIA antibody response to P. haemolytica antigens in
sheep vaccinated with Ovipast-9-IRP vaccine
78
FARM D
Fig. 5.1d. Mean IHA antibody response to P. haemolytica antigens

















Fig. 5.2a. Antibody response to P. haemolytica A2 35K IRP in sheep
vaccinated with Ovipast-9-IRPR vaccine
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Fig. 5.2d. Antibody response to P. haemolytica A2 35K IRP in sheep
vaccinated with Ovipast-9-IRP vaccine
83
Fig. 5.3a. Antibody response to P. haemolytica anti-Al capsular antigen in
sheep vaccinated with Ovipast-9-IRP vaccine
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Fig. 5.3b. Antibody response to P. haemolytica anti-Al capsular antigen
sheep vaccinated with Ovipast-9-IRP vaccine
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Time post-vaccination (weeks)
Fig. 5.3c. Antibody response to P. haemolytica anti-Al capsular antigen in
sheep vaccinated with Ovipast-9-IRP vaccine
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Time post-vaccination (weeks)
Fig. 5.3d. Antibody response to P. Iiaemolytica anti-Al antigen in sheep





Farm A Farm B Farm C Farm D
Fig. 5.5. Death due to pneumonic pasteurellosis in the 1RP vaccine trial
sheep farms in the year 1992-1993.
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after the second injection. The mean OD of the unvaccinated control was 0.2 on day 0
and changed little until week 5.
In all the vaccinated farms the production performance in terms of animal
survivality during the outbreaks ofpasteurellosis during the trial period (1992-1993) was
improved as compared to non-vaccinated farms. Although these mortality figures were
not significantly different (P>0.05), the vaccinated farms recorded reduced ewe and lamb
mortality. Unvaccinated flocks had 10%, 6%, 3% and 12% higher total annual sheep
mortality due to pasteurellosis in farm A, farm B, farm C and farm D respectively
compared to vaccinated flocks ( Figure 5.5).
5.1.4 Discussion
In this study the magnitude of antibody response against 35 kDa IRP
antigen, anti-Al capsule and IHA antibody in conventional sheep vaccinated with a
novel vaccine containing iron-reguaited proteins (Ovipast-9-IRPR, Hoechst, UK) was
measured. A high level of antibody response against these antigens was demonstrated
as has previously been reported by other investigators ( Donachie et a/., 1988, Gilmour
etal, 1991 ).
As it is not possible to produce pneumonic pasteurellosis regularly in
conventionally reared sheep by exposure to aerosols ofP. haemolyticci or intratracheal
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inoculation, the assessment of vaccine efficacy was based on the measurement of the
serum antibody titres. There were wide variations in the serum IHA antibody titres. In
vaccinated animals at the start of the trial the serum antibody titres ranged from 8 to
128 and in unvaccinated controls ranged from 4 to 128. The considerable differences
in the mean titres between groups of vaccinated and unvaccinated sheep were not
significantly significant (p>0.05) because of these wide ranges ofvalues. However, after
vaccination, the IHA titres of the vaccinated animals increased significantly compared
to unvaccinated counterparts resulting in significant values (p<0.05). The pattern of
response to 35 kDa IRP antigen and anti-Al capsule was similar to the IHA responses.
The results of the serological studies on farms A, B, C and D at the
commencement of study were very similar. A high percentage of the sheep had
detectable antibodies against 35 kDa IRP and high antibody levels to A1 capsule antigen
and IHA titres. Higher OD readings in the sera of the animals at the start of the
experiment are to be expected because of earlier exposure of the conventional animals
to the infection of P. hciemolyticci.
In farm C, higher ELISA and IHA antibody levels were observed in many
lambs. This was probably due to maternal antibodies in the colostrum of the positive
ewes. The results were to be expected because strict vaccination against pasteurellosis
was practised in the farm. The titre of these passive antibodies rapidly decreased to reach
a minimum three months later. However large number of lambs in farm D, where
vaccination programmes were also included in their husbandary practices, had much
lower ELISA antibody levels and IHA titres when compared to the other farms and
some of the lambs had negative titres. The explanation for this situation could possibly
be due to improper handling of the vaccines or the animals were not vaccinated as
recommended.
Serological monitoring studies indicate that the vaccine stimulated a good
response in vaccinates although a high level of non-specific reactivity was observed in
a number of animals in the control and vaccinated group. Sera from vaccinated and non-
vaccinated sheep were tested by ELISA for 35 kDa IRP antibodies, capsular A1
antibodies and IHA titres. All vaccinated animals had high ELISA antibody levels and
high IHA titres after first vaccination. The antibody levels increased rapidly after
booster, but declined sharply after that. Peak immune responses were observed 1 week
after first vaccination, but then declined rapidly in most animals when tested for IRP
antibodies. In sheep which were vaccinated twice, the titres clearly increased after the
second vaccination. Control animals had low antibodies levels to all the antigens tested.
Although there is some doubt as to the protective value of serum alone
(Wells etal., 1979) and therefore of the significance of serum antibody titres, the titres
reported in this trials are of the same order as those obtained in SPF lambs given the
same vaccine to lambs and shown to have been protected on challenge (Gilmour et ai,
1991).
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The study indicates that vaccination alone with vaccine containing IRP
results in high immunogenicity and high protection of sheep under field condition. It
appeared that the IRPs vacccine stimulated the sheep immune system to elicit antibody
response to protect sheep against clinical pasteurellosis.
However, six months after the vaccination trials, the serum antibody levels
of ewes tested on farms A and B were lower than at the beginning of the study, some
of them even below the positive threshold. Therefore the duration and quality of the
immunity conferred by the vaccination warrants further examination. Further evaluation
has to be carried out to permit confirmation of the effectiveness of the dosage of the
vaccine, the vaccine schedule and the timing of the booster dose.
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5.2 Evaluation of a new P. haemolytica IRP vaccine (Ovipast-9-lRPR, Hoechst,
UK) against experimental P. haemolytica A2 challenge in conventional
sheep
5.2.1 Introduction
Development of improved P. haemolylica vaccines for sheep and goats
has progressed markedly since it has been possible to reproduce pneumonic
pasteurellosis experimentally (Gilmour et al., 1983). However, a major limitation has
been the necessity to rear lambs in specific pathogen free (SPF) conditions for such
experiments. Although conventional animals may have pre-existing experience of P.
haemolytica infection, it was considered worthwhile to attempt vaccination-challenge
experiments in conventionally reared lambs.
This study was conducted to test the efficacy of a novel P. haemolytica
vaccine containing iron regulated proteins (Ovipast-9-IRPR, Hoechst, UK) against
experimental P. haemolytica A2 challenge.
5.2.2 Materials and Methods
Animals and experimental design: These were lambs from a mixed
breed of Dorset-Malin sheep. The lambs were randomly allocated to vaccinated and
unvaccinated control groups and were housed in isolation pens in groups of ten with
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equal numbers of vaccinates and controls. They were fed with cut grass and water ad
lib and concentrates given at 200 g/head daily.
Experimental design
Vaccination * Vaccination Challenge
Group( n=I0)
Vaccinated 7 35 47
Unvaccinated 47
*- days after commencement of trials
Vaccines and challenge infection: The lambs were vaccinated
subcutaneously (2 ml dose) with two doses ofOvipast-9-lRPR vaccines with an interval
of 28 days between injections. The animals were bled for serology by jugular
venipuncture (10 ml vacutainers) before vaccination at days 0 and weekly for 6 weeks.
The lambs were subjected to transportation stress followed by three consesecutive
injections of 10 mg per lamb of dexamethasone (DexasoneR, Atlantis, Germany) and
after the last dexamethasone injection the animals were immediately infected intra-
tracheally with inoculation of 6 ml suspension of P. haemo/ytica A2 ( 2 x 109cfu /ml).
Clinical and pathological assessment: The clinical appearance of each
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lamb was monitored for 72 h after infection. Any lambs which died were examined
post mortem. Samples were taken for bacteriological examination. Clinical and
pathological findings were scored by methods described by Gilmour et al., (1983). The
daily clinical score for each lamb was calculated on the basis points alloted to dullness,
respiratory abnormality and fever. The lambs that survived after 3 days post-challenge
were euthanised with 10 ml of saturated magnesium sulphate per animal intravenously.
Necropsies were carried out immediately and samples sent for bacteriological and
pathological examinations.
Serological Methods: Sera were analysed for IHA antibody and for
specific antibody to 35 kDa 1RP antigen and anti-Al capsule using EL1SA, as described
in the general Materials and Methods.
5.2.3 Results
The group mean clinical, lung, bacteriological and total disease scores
are shown in Table 5.3a.
Clinical observations: Six hours after exposure to P. haemolytica A2
challenge two lambs in the control group were severely affected while three others
were dull and anorexic. Two lambs in the control group died 24 h later. Febrile
condition were observed in five of the ten vaccinated lambs but all the lambs survived,
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though one was dull, but still standing. No other clinical abnormality were observed.
At necropsy, the lung lesions characteristic of pasteurellosis were noted
in 3 of the unvaccinated animals. Profuse pure growth of challenge organisms were
isolated from those lesions. The histologic appearance of the lesions was that of a
supparative bronchopneumonia with alveolar collapse. There was infiltration of
polymorphs in the bronchioles and serum leakage and several multinucleate giant cells
were present. Findings were consistent with P. haemolytica pneumonia..
No specific lesions were visible in the lungs of the 1RP vaccinates, but
acute congestion and petechiation over the heart were visible in 3 of the animals. P.
haemolytica was recovered in two of the lungs.
The IRP vaccinates had mean total disease scores that were 2.7 times
lower than those for unvaccinated animals but not significantly different (p>0.05)
(Table 5.3a).
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Table 5.3a. Group mean clinical, bacteriology, lung lesion and total disease
scores for sheep vaccinated and unvaccinated with Ovipast-9-IRPR
vaccine.
Vaccine Clinical Lung Lesion Bacteriology Total Disease
Score (± SE) Score (± SE) Score (± SE) Score (± SE)
Ovipast-9- 1.8±0.66 l.G±0.67 0.8±0.53 3.6±1.5
IRPR vaccine
Unvaccinated 5.4±1.7 3.0±1.5 2.4±1.2 9.6±4.1
(control)
Serological evaluation: The results of the serum antibody responses to 35 kDa ERP of
A2 and anti-capsualr antigens measured by ELISA are shown in Table 5.3b. The Figures
5.4 - 5.6 showed the serum antibody responses to P. haemolytica A2 35 kDa IRP and
anti-Al capsule antigens and IHA response plotted against time post-vaccinations.
Table 5.3b. Serum IHA titres and antibody response to 35 kDa IRP of P.
haemolytica A2 and anti-Al capsular antigens measured by ELISA
in sheep vaccinated with Ovipast-9-IRPR vaccine.
Ovipast-9- 0.12±0.001 0.29±0.021 0.71±0.035 1.37±0.03 9.6±1.5 166.4±26
IRPR vaccine
Unvaccinated 0.11±0.005 0.19±0.04 0.4±0.032 0.38±0.03 6.4±1.2 15.6±3.1
(control)
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Fig. 5.4. Mean IrlA antibody response to F. haemolyiica A2 antigens in
sheep vaccinated with Ovipast-9-IRPR vaccine
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Time-post vaccination (weeks)
Figure 5.5. Antibody response to P. haemolyticu A2 35 kDa




Fig. 5.6. Antibody response to P. Jiaemolytica anti-AJ capsular antigen in sheep
vaccinated with Ovipast-9-IRPR vaccine
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Serology indicated that the vaccine stimulated a good response in vaccinates,
although a high level of non-specific reactivity was observed in the both groups.
Sera from vaccinated and non-vaccinated sheep were tested by ELISA for
35 kDa IRP and anti-Al capsular A1 antibodies. There were significant differences
(P<0.05) in the mean antibody titres against the antigens tested between vaccinated and
unvaccinated groups. There was also a rise in IHA titres in the vaccinated group but due
to the wide range of titres recorded (between 1:4 to 1:256) the differences between the
groups were not statistically significant (p>0.05)
5.2.4 Discussion
Although there were no significant differences (P>0.05) in the total disease
scores between vaccinated and the unvaccinated controls animals, more lambs died in the
control group. However, vaccinated animals had higher mean antibody titres against the
antigens tested and it appeared that high titres were correlated with protection against
clinical pasteurellosis. The results are in agreement with that reported by Gilmour et al.
(1991) who demonstrated that P. haemolytica A2 extract vaccine containing IRPs
protected SPF lambs. Previously, protection against disease caused by A2 serotype has been
demonstrated in SPF lambs recovered from experimental infection (Donachie et al., 1986)
or passively protected with immune serum (Jones et al., 1989).
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Antibody response was elicited in vaccinated animals against 35 kDa 1RP
antigen and anti-Al capsule. High IHA titre was also elicited in the vaccinated group.
However, a few control unvaccinated lambs also showed strong antibody responses. This
may due to cross reactivity with other other bacterial species since P. hacmolytica is not
present in any of the lambs prior to challenge.
The results from this study demonstrated that there was some indication of
protection afforded by Ovipast 9 1RPr vaccine in the vaccinated conventional animals.
However, the reproducibility of the results may be poor due to the nature of on non¬
specific immune reactions in conventional animals as opposed to SPF animals. More
challenge exposure studies using conventional animals are suggested for the future to
evaluate the degree of protection conferred by this vaccine against pneumonic
pasteurellosis.
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CHAPTER 6.0 PRODUCTION OF P. HAEMOLYTICA SEROTYPE
A2 POLYSACCHARIDE CAPSULE
The antigens responsible for conferring protection against certain P. haemolytica
serotyypes A are known to be contained in extracts prepared by sodium salicylate, saline
and phenol treatment from these cells (Gilmour et al., 1979 and 1983). These extracts
are presumed to contain surface components and they include the serotype specific
antigen as sheep vaccinated with this extract in adjuvant produce high levels of antibody
against the serotype antigen (Wells et al., 1979).
Identification of the specific antigen or antigens involved in protection would
help in understanding the immunology of the disease. Adlam et al. (1987) have shown
that capsular polysaccharide from culture supernatant ofP. haemolytica serotype A2,
the most common serotype isolated from pasteurellosis cases in sheep, has a capsular
structure identical to the capsular polysaccharide (also known as colominic acid) ofN.
meningitidis group B and E. coli Kl; an «t(2A8)-linked heteropolymer of N-acetyl
neuraminic acid.
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The conditions governing the production of colominic acid and dextran (a-1,4-
linked dextran) polymers ofP. haemolytica A2 organisms remain to be evaluated. The
aim ofthese series ofexperiments were to determine the optimum production conditions
for A2 capsule polysaccharide.
6.1 Extraction of capsular material from P. haemolytica serotype A2
6.1.1 Introduction
A soluble capsular material was demonstrated when P. haemolytica was
cultured overnight on a fresh beef infusion agar plate (Carter, 1956). The author stated
that this substance was polysaccharide in nature and removed it from organisms by
heating a culture of P. haemolytica at 56° C for 30 min in water or normal saline
solution. P. haemolytica cultures produced capsular material early (4 to 6 h) in their
growth cycle as demonstrated by the direct flourescent antibody (FA) technique, using
antiserum to whole organism (Gentry et al., 1981). By this technique the author further
showed that the capsule was found to dissappear gradually as the culture aged so that
little capsule material remained on the cells after approximately 16 to 22 h of incubation.
The purpose of this study was to estimate the yield of this capsule
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produced from the different growth phase of P. haemolytica A2 in different types of
culture media.
6.1.2 Materials and methods
P. haemolytica A2 (strain EO-200) cells were grown in three different types of
media, viz. nutrient broth, brain heart infusion and trypticase soya broth. They were
cultured at different incubation times as shown in Table 6.1.
6.1.3 Results
The production of capsular materials in the various culture media at different
duration of culture is shown in Table 6.1. Sialic acid determination indicates the
amount of colominic acid produced.
There were no significant differences in terms of sialic acid and protein content
composition between the media tested (P>0.05). The production of sialic acid and
protein was highest in the 6 h culture in nutrient broth, but are not significantly
different when compared to the 18 h or 24 h culture (p>0.05). The nutrient broth
(Gibco, No. 2) at 6 h culture supported 6 x 10s cfu/ml viable counts of P. haemolytica
A2 and contained 1.7 mg/ml protein and 0.06 mg/ml sialic acid respectively.
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Table 6.1 Protein and Sialic acid determination on the P. haemolytica A2
capsular extracts"









V 6.5 x 108 4.8 x 107 5.1 x 106
6 h P 1.7 0.8 0.7
S 0.06
0.04 0.06
V 6.0 x 108 4.1 x 107 4.0 x 106
18 h p 1.25 0.8 0.85
s 0.06 0.05 0.04
V 4.1 x 105 3.1 x 104 4.0 x 104
24 h p 1.2 1.0 0.8
s . 0.05 0.04 0.05
V - viable counts (cfu/rnl)
S - average sialic acidconcentration(mg/ml)
P - average protein concentration (mg/ml)
a - average results from 4 trials
6.1.4 Discussion
The capsular extracts were shown to contain protein and sialic acid. It was not
clearly understood how much of these components were leached from the cell interior
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and how much were truly of capsular origin. Gentry el al. (1981) showed that cells
from early logarithmic phase cultures ofP. haemolytica A1 were encapsulated and the
capsular material disappears gradually as the culture ages. In this study it was shown
that capsular material could be maximally recovered from the early phase culture. The
amount of sialic acid present was relatively constant (0.04-0.06 mg/ml) regardless of
different culture media used. The protein content however varied greatly ranging from
0.7-1.7 mg/ml culture supernatant. The nutrient broth extracts contained 2-2.5 times
more protein than that obtained from either BUI or TSB media and 1.5 times more
sialic acid than BH1 media. These differences were thought to be due to the availability
of more nutritive products to support better growth of encapsulated cells of the
bacteria.
From these results it can be shown that the media and the period of culture of
choice for extracting maximal amount of protein and sialic acid from A2 cells was
determined to be a 6 h culture nutrient broth media.
6.2 The effect of temperature on the production of capsular materials of P.
haemolytica A2
6.2.1 Introduction
Earlier experiments have demontrated that cultures of P. haemolytica
produce optimal capsular materials at 6 h in their growth cycle in nutrient broth culture.
Suspension media and extraction temperatures have been shown to influence the yield
of the capsular materials (Gentry et al., 1981). The purpose of the present study was
to determine the optimal extraction temperatures for maximal production of P.
haemolylica A2 capsular materials grown in solid and liquid culture media.
6.2.2 Materials and Methods
6.2.2.1 Extraction of capsular materials of P. haemolytica A2 grown on solid
media ( Blood Agar)
P. haemolylica A2 ( strain EO-200) was cultured on twelve 9 cm. blood
agar plates and incubated for 6 h. Confluent growth was carefully removed and
suspended in 20 ml PBS. The bacterial suspension was heated in a water bath at
different temperatures viz., at 37'C and 41 *C followed by centrifugation at 17 000 g for
15 min. The supernatant was removed and sterile filtered through 0.2 membrane
( Millipore, UK).
Viable counts were performed on the pre and post-extraction bacterial
supernatant by the spot-plate method. Protein and sialic acid content were measured
as described in the general Materials and Methods.
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6.2.2.2 Extraction of capsular material of P. haemolytica A2 grown in liquid
media (Nutrient Broth)
P. haemolytica A2 (Strain EO-200) was grown in 20 ml nutrient broth (Gibco
No. 2) and incubated at 37°C overnight. The seed culture was inoculated in 1 litre
nutrient broth. Half of the bacterial culture was incubated at 37°C and the remainder
incubated at 41^ in a water bath for 6 h. The bacterial suspension were centrifuged at
17 000 g for 15 min and viable count, protein and sialic acid composition were
measured as described in the general Materials and Methods section.
6.2.3 Results
The production of capsular materials on blood agar and in nutrient broth at
extraction temperatures of 37"C and 41° C is shown in Table 6.2
The growth ofP. haemolytica was significantly better in the solid media (blood
agar) with 3.3 x 102cfu/ml more viable counts compared to the liquid media (nutrient
broth) (P<0.05). The growth was not affected by the temperature under study.
However, when comparing the composition of the sialic acid and protein between the
media it was found that there were no significant difference in sialic acid and protein
content composition (P>0.05). The production of protein was found to be higher in
nutrient broth culture at both extraction temperatures. This possibly could be due to
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more capsular materials leached into the liquid environment.
Table 6.2 Effect of temperature on the yield of protein and sialic acid in the




37°C 41°C 37°C 41°C
V V P S P s
Nutrient 6.4 x 108 6.4 xlO8 1.7 0.06 1.73 0.06
Broth
Blood
Agar 2.1x10" 1.3x10" 1.55 0.06 1.51 0.06
V - viable counts (cfu/ml)
P - Protein concentration (mg/ml)
S - Sialic acid concentration (mg/ml)
a - average of 3 trials
6.2.4 Discussion
Capsular material has been shown to be produced optimally from 6 h
cultures ofP. haemolytica A2 in nutrient broth and the yield of protein and sialic acid
composition is not affected by either extraction temperature, 37° C or 41° C. Gentry
et al. (1981) also demonstrated that capsular material may be removed from young
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cultures ofP. haemolytica A1 by 1 h incubation ofPBSS suspended cells at 41 °C. They
suggested with this treatment there was a little loss of cell viability until the extraction
temperature reached 45"C. At higher temperatures of 45 "C or 56*€ Gentry el al. (1981)
demonstrated that capsular extracts prepared in water contained less protein than did
extracts prepared from the same suspension at 37°C or 4 PC, possibly due to the
breakdown at the higher temperatures of protein into polypeptides too small to be
recognized by the protein assay. They also showed that there was increase in cell lysis
and leakage of PBSS suspensions incubated at 45°C or 56°C than those incubated at
4 PC or less.
This study has indicated that optimal production of capsular material could be
obtained from cells grown in nutrient broth in the early logarithmic phase cultures (6
hours) incubated at 37X1 The capsular material was optimally extracted with minimal
cell destruction in PBS suspension incubating at 37°C for 1 hour.
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CHAPTER 7.0 THE IMMUNOCHEMICAL ANALYSIS OF OMP-PS
COMPLEX OF P. HAEMOLYTICA A2 AND ITS
IMMUNOGENICITY IN MICE
Capsular polysaccharides (PS) are recognised as important attributes of
pneumonia inducing bacteria. Capsular polysaccharides ofN. meningitidis group B and
E. coli K1 have been purified and characterised physico-chemically, biologically and
immunologically (Kasper et al., 1973; Robbins et al., 1974; Bhattacharjee et al., 1975)
and their role in the mediation of pneumonia has been described (Lifely et al., 1984)).
P. haemolytica A2 strains have been shown to produce PS (Gilmour et al., 1985;
Adlam et al., 1987), but there is a descrepancy with respect to their physico-chemical,
biological and immunological characteristics as reported by different workers (Gilmour
et al., 1979; Donachie et al., 1989).
P. haemolytica A2, the most commonly isolated serotype from sheep
pasteurellosis has a capsular structure identical to the capsular polysaccharides of the
human meningitis organisms N. meningitidis group B and E. coli K1. The polymer is
a colominic acid of an a-(2->-8)-linked heteropolymer of N-acetyl neuraminic acid
(NANA). This capsular structure is known to be an extremely poor irnmunogen and it
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has been suggested that immune tolerance, loose configuration and host
neuraminidases allow organisms with such PS to evade detection by host defences
(Lifely et al., 1987).
Attempts to induce immunity to group B meningococci and E. coli K1 have
limited success because polymers of an a-(2->8)-linked NANA, alone or complexed
to outer membrane proteins, induced low transient levels oflgM antibodies (Wyle et
al., 1972; Lifely et al., 1991). However, purified B polysaccharides noncovalently
complexed to outer membrane proteins of N. meningitidis have shown promising
results vvhen tested for their immunogenicity in mice (Peppier et al., 1982; Zollinger
et al, 1978). The availability ofmonoclonal antibodies with specificity for the capsule
antigen ofN. meningitidis group B and a polysaccharide complexed to outer membrane
meningococcal vaccine prompted research to evaluate its efficacy in mice against P.
haemolylica A2 challenge.
This study reports purification and characterisation of purified OMP-PS
complex material from culture supernatant of P. haemolylica serotype A2 and its
contribution as vaccine component against pasteurellosis in mice and sheep.
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7.1 The chemical anaysis of outer-membrane protein polysaccharides (OMP-PS)
of P. haemolytica A2
7.1.1 Introduction
Capsule preparations ofmany Gram-negative bacteria can be hydrolysed
and the components can be isolated by centrifiigation and chromatography (Adlam el a/.,
1985). The capsule isolated can then be fractionated and analysed. This section describes
the isolation, fractionation and analyses of the OMP- polysaccharide complex of P.
haerno/ytica A2.
7.1.2 Materials and Methods
The crude complexes were chromatographed on a Sepharose CL-2B
column as described in the general Materials and Methods. The ELISA, PAGE and dot
blotting procedures are as described in Chapter 3. Sheep antiserum raised against A2
SSE was used at dilution 1 in 500 as the detecting antiserum. Convalescent sheep serum
from sheep recovered from experimental pasteurellosis was used at dilution 1 in 50 as
the positive control serum.
The complex was analysed for LPS, nucleic acid, protein and sialic acid
by the method given in the general Materials and Methods.
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7.1.3 Results
Yield ofOMP-PS complex: Using the purification method as described
in the Figure 3.1, the yield ofcrude OMP-PS complex ofP. haemolytica A2 (strain E0-
200) per litre of culture supernate was 0.12g.
When the complex was further purified (Figure 3.2), the yield of purified
OMP-PS complex was 11.4 mg (9.5% by weight) of the crude complex. The protein and
sialic acid (carbohydrate) composition of OMP-PS complex are shown in Table 7 1.
The protein to carbohydrate ratio was 4:1. No attempt was made in these
experiments to optimise yields of this complex by for example, alterations of bacterial
growth conditions or cetavlon concentration.
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Table 7.1 Protein and sialic acid determined in a preparation ofOMP-PS complex
of P. haemolytica A2.
Preparation Protein Sialic acid Ratio of protein/
(mg/ml) (mg/ral) sialic acid
Crude complex 1.1 0.72 1.5
Purified complex 0.08 0.02 4.0
(V() from Sepharose CL-2B)
Physical and chemical analysis: The purified OMP-PS polymer was
a white powder and soluble in water. The molecular weight was in excess of 106. Gel
filtration of the crude complex in Sepharose CL-2B removes low-molecular weight
nucleic acids and salts which appear in the total volume (VT) of the column as well as
polysaccharides not associated with the complex at the void volume (V(1). The purified
complex (void volume peak) was easily sterile filtered through 0.45 and 0.2 //m
membranes (Millipore, UK).
Chemical analysis of the crude and purified polymer revealed very little
LPS present (0.06% of total amount of complex) when analysed with kinetic
turbidimetric assay method using Limulus Amoebocyte Lysate (LAL).
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Column chromatography: The elution patterns obtained when crude complex samples
were chromatographed on Sepharose CL-2B are shown in Figure 7.1. The fractions
were assayed for sialic acid and protein composition.
When assayed for sialic acid and noncovalently bound protein, the crude
complex was shown to elute from the column fraction numbers 18-24. Only a small
fraction of the sialic acid content is found in the earlier fraction. The greater proportion
is found in the later fraction, which does not show any antigenic activity (results not
shown).
Dot blotting results using monoclonal antibodies with specificities for N.
meningitidis group B capsule and polyclonal antibodies from purified OMP-PS of P.
haemo/ytica A2 vaccine showed that there is strong reaction with the main fraction of
the purified material ( Figure 7.2).
SDS-PAGE: Sodium dodecyl sulphate-poiyacrylamide gel
electrophoresis (SDS-PAGE) of both crude and purified OMP-PS complex is presented
in Figure 7.3 (Lane 2 and 3, respectively). For comparison, the SDS-PAGE pattern of
the envelope of the P. haemolyiica A2 grown in nutrient broth is also shown (Figure 7.3,
Lane 4 ). Fewer protein bands were present in the crude OMP-PS complex, with 2
major bands at 30 kDa and 42 kDa were present. One major band at 42 kDa is present
in the purified fraction.
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Figure 7.1 ICIutioit profile of (he cctavlon precipitated capsular materials of"P.
hacmolytica A2 on Sepharosc C'I^-2H . Fractions ( 60 x 9 ml) were
elulcd xvitli ammonium sulphate buffer and assayed for sialic acid
and protein.
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Figure 7.2. Dotblot of different fractions of purified OMP-PS complex material
of P. Itaemolytica A2 from Sepharose CL-2B column reacted with
antisera raised against a) Purified OMP-PS vaccine, Grid A5-D5;
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Figure 7.3 SDS- PACE of P. haemolytica A2 outer membrane protein
complexed to polysaccharide obtained in the purification
desribed in Fig. 4.1. Lane 2 contained a crude OMP-PS and
lane 3 contained a purified OMP-PS complex material. Lane
4 contained A2 envelope grown in nutrient broth. Molecular
mass markers are shown in lane 1. Each lane contained




This compares with the outer membrane protein profile obtained from the
envelope ofP. haemolytica A2 whereby the major bands at 30 kDa and 42 kDa were
present (Donachie & Gilmour, 1988). Squire et al. (1984) also demonstrated that P.
haemolytica A1 contains major outer membrane proteins of similar molecular mass.
From the results, it can be proposed that the purified complex is
composed of mainly carbohydrate, a proportion of outer membrane protein and
minimal amounts of LPS and nucleic acid.
7.2 The immunogenicity of OMP-PS of N. meningitidis group B against P.
haemolytica A2 challenge in mice
7.2.1 Introduction
Vaccines containing antigens of P. haemolytica serotype A2 have been
comparatively poor immunogens in mice, rabbits and sheep (Gilmour et a/., 1983;
Evans et al., 1979; Donachie et al., 1988). A high degree of immunity against A2
serotype has been reported only for lambs recovered from experimentally induced
pasteurellosis (Donachie et al., 1986). Suboptimal efficacy of some Pasteurella
vaccines against experimental A2 challenge may be explained by the limited range of
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antigens on the surface ofbacterial cells or the antigens may not be presented in a right
conformation to the host immune system.
In N. meningitidis group B and E. coli K1 the capsule has been identified
as a virulence factor and a protective antigen (Schiffer et al., 1976). The murine
monoclonal antibodies with N. meningitidis group B specificity has been shown to
protect mice against challenge (Moreno el al., 1983). P. haemolytica serotype A2, the
most commonly isolated serotype from pasteurellosis cases in sheep has a capsular
structure identical to /V. meningitidis group B ( Adlam et ul., 1987). The availability
of monoclonal antibodies with specificity for the capsule antigen of N. meningitidis
group B and a polysaccharide-outer membrane protein complex meningococcal vaccine
prompted an examination of the contribution to immunity made by antibodies to P.
haemolytica A2 capsule.
Although not a natural host, the septicaemic mouse model for
pasteurellosis (Evans & Wells, 1979) offers a mean of assessing the efficacy of
vaccines and the potential of antibody for passive protection.
7.2.2 Materials and Methods
P. haemolytica A2 (strain A713) was grown in nutrient broth (Gibco No.
2) for 18 hours at 37°C. Cells for mouse challenge were pelleted by centrifugation at
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3,000 g for 20 minutes before resuspension in phosphate buffered solution (PBS), pH
7.4. Cells for immunoblotting were centrifuged as above but resuspended in distilled
water. Whole cell preparations of N. meningitidis and P. huemolytica were separated
by SDS-PAGE and transferred to Immobilon P (Millipore). The blots were probed with
mouse antisera and sheep anti mouse IgG-HRP conjugate (SAPU) was used to detect
bound mouse antibodies. For bactericidal and opsonophagocytosis assays, the methods
described by Sutherland, (1988) and Donachie et. al. (1986) were used.
N. meningitidis group B type 6 (srain CN7622) was grown in 5% sheep
blood agar for 18 hours at 37°C, harvested in PBS, pelleted by centrifugation at 3,000
g for 20 minutes before resuspension in distilled water.
Mice immunisation and challenge: C57 black mice (6 weeks old) were
passively immunised with monoclonal antibodies or control positive or negative sera
one hour before challenge. For vaccination, meningococcal vaccine (Wellcome
Biotech) at l^g/dose was given intraperitoneally twenty and ten days before challenge.
For challenge the mice were injected intraperitoneally with 1OLD50 of P. haemolytica
A2 in 80% hog gastric mucin. Five hours after challenge, the mice were humanely




The activity of the eight monoclonal antibodies in the 1HA test,
bactericidal and opsonophagocytic assays are shown in Table 7.2.
Seven antibodies demonstrated an IHA titre with serotype A2 antigen and
the titres ranged from 1/80 to 1/320. A low titre cross reaction was observed with
serotype T10. Little or no activity was observed with any of the antibodies in the
bactericidal or opsonophagocytic assays.
Two antibodies with IHA activity (34A10 and 62A13) were assessed in
a passive mouse protection test where the mice were challenged with serotype A2
(Figure 7.3). The results show that significant protection was observed on two
occasions for antibody 62A13 (P<0.05) and on one occasion for antibody 34A10.
The contribution of capsular antigen to immunity and the efficacy of
direct immunisation was assessed by immunising mice with a meningococcal
polysaccharide-OMP vaccine and challenging with serotype A2. The results of this
immunisation are shown in Figure 7.4. Significant protection was conferred on mice
by the vaccine (P<0.05). Assay of the serum antibodies of immunised mice by the IHA
test indicated high titres in a number of animals to serotype A2 capsule.
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Table 7.2. The 11IA titre, bactericidal activity (%K) and opsonophagocytic







14A2 20 <5 ND
22A2 320 <5 ND
32A1 0 <5 7
34A10 •80 <5 ND
35A1 320 <5 ND
36A10 320 <5 ND
62A13 160 <5 ND
85A5 80 <5 ND
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mAb mAb Control Control
34A10 62A13 +ve -ve
Fig. 7.4. Passive protection of mice to P. haemolytica A2 challenge by






Fig. 7.5. Protection of mice to P. haemolyticn A2 challenge by
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Figure 7,6. Immunoblot of TV. meningitidis group B whole cells
probed as follows: Lane 1-7, mouse antisera raised
against Meningococcal group B vaccine;
Lane 8, mouse antisera raised against P. haemolytica
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Figure 7.7. Immunoblot ofP. haemolytica A2 whole cells probed
as follows: Lane 1-7, mouse antisera raised against
Meningococcal group B vaccine; Lane 8, mouse
antisera raised against P. haemolytica A2; Lane 9,
serum from nonimmunised mice
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Sera from vaccinated mice were examined in immunoblots against N.
meningitidis and P. haemolytica whole cells to determine the antibody response to
cellular proteins (Figure 7.6 and 7.7). Very little response was observed to P.
haemolytica antigens but a strong response was observed to N. meningitidis antigen of
around 43 kDa.
7.2.4 Discussion
Monoclonal antibodies with specificities for N. meningitidis group B
capsule protected mice against P. haemolytica A2 challenge. Similar protection has
previously been shown against E.coli K1 challenge (Moreno et al., 1983). The results
reported are in agreement with that of Moreno et al. (1983) who succesfully produced
murine monoclonal antibodies with group B specifities and showed their protective
value in mice against N. meningitidis challenge. It also indicated the shared protective
antigens in the capsular polysaccharide structure ofN. meningitidis group B and E. co/i
K1. The poor immunogenicity of purified group B polysaccharide is well documented
(Frasch el al., 1978; Gotschlich et al., 1978). The polysaccharide does not induce
specific antibodies, and the response against whole bacteria, or the polysaccharide in
a complexed form, is relatively short lived and consists almost exclusively of IgM
antibodies (Zollinger et al., 1978, 1979). It has been suggested that immune tolerance,
loose configuration and host neuraminidases may all contribute to this (Lifely et al.,
1987). These factors may also explain the comparatively poor immunogens of serotype
A2 capsular antigen in mice ( Gilmour et al., 1983).
In this study the protective value of monoclonal antibody to group B
polysaccharide was demonslialed. The results confirm the importance of antibodies to
colominic acid capsules in protection.
Previous attempts to immunise mice with B polysaccharides covalently
complexed to outer membrane proteins were not succesful (Jennings el al., 1981). In
lambs, the A2 capsular antigen did not induce an antibody response ( Donachie et al.,
1986). In this study the results has shown that meningococcal vaccine protected mice
against A2 infection. The findings suggest that the antigens are presented in the right
way thus increasing its immunogenicity in mice. The results in this study are the first
demonstration of direct immunisation against A2 infection in the mouse model,
however, the mechanism of protection is unclear as both bactericidal and
opsonophagocytic activity could not be demonstrated.
P. haemolytica vaccines with a similar composition to the meningococcal
vaccine should be evaluated in ruminants for efficacy against experimental
pasteurellosis.
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7.3 The immunogenicity of OMP-PS of P. haemolytica A2 in mice
7.3.1 Introduction
Previous experiments have shown that mice were protected when passively
immunised with monoclonal antibodies with specificity for capsule antigen of N.
meningitidis group B and a polysaccharide-outer membrane protein complex
meningococcal vaccine. Further immunisation of the mice with N. meningitidis capsule-
OMP complex also confers protection in the mice. Since the A2 capsule antigen is
identical to N. meningitidis it follows that the A2 capsule is potentially an important
protective antigen.
In the experiments in Chapter 6, the purified capsular complex material
was extracted and chemically characterised. This experiment was conducted to
demonstrate the protection afforded by vaccination with this purified A2 capsular
polysaccharide-OMP A2 vaccine in mice.
7.3.2 Materials and Methods
Mice immunisation and challenge
Experiment 1: Fifty mice were randomly allocated to five groups of 10
mice each. The layout of the experiment is shown in Table 7.3. Details of the vaccine
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preparations are given in the general Materials and Methods.
Experiment 2: In this experiment, groups of mice immunised with OvipastR
•*
vaccine and leukotoxin materials were included in the experimental design to
determine the protective value of IRP and leukotoxin antigen in mice. The layout of
the experiment is shown in Table 1A. Details of the vaccine preparations are given in
the general Materials and Methods.
Three weeks after the second vaccination, inocula ofP. hacmolytica A2 in gastric
mucin were prepared and used to challenge the mice. Viable counts were performed
on the livers of invidual mouse six hours after challenge. Viable counts are expressed
as log,0 cfu.
Serology: Immunoblotting and IFIA tests were performed as described in the
general Materials and Methods.
7.3.3 Results
The results of experiment 1 are summarised in Table 7.3. All the
vaccinated mice had lower liver counts than did the unvaccinated controls but only the
mice vaccinated with purified A2 OMP-PS complex and meningococcal group B
vaccines were significantly different (P<0.005) from the controls counts. There is some
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indication that the degree ofprotection conferred by the purified A2 OMP-PS complex
vaccine is better (1.3 cfu), although not significantly different from the meningococcal
B vaccine (1.8 cfu).
The results of experiment 2 are summarised in Table 7.4. The experiment
again demonstrated that all vaccinated mice had lower liver counts than did the
unvaccinated controls but only the mice vaccinated with purified OMP-PS complex,
meningococcal group B vaccine, Ovipast and a mixed purified OMP-PS vaccines were
significantly different from the control counts (p<0.004). The protective value of the
Ovipast vaccine was similar when the vaccine was enriched with the purified OMP-PS
A2 complex material. In contrast, the leukotoxin vaccine did not protect the mice.
However, when the purified OMP-PS A2 complex material was added to it, significant
protection ofmice was demonstrated (p<0.004).
Serology: The results of immunoblotting of sera from all the groups of
vaccinated and control mice against P. haemolytica A2 antigens are shown in Figure
7.8 and Figure 7.9. The IIIA test gave inconclusive results in that there was no
measureable IHA titre in all groups but some individual mice immunised with purified
OMP-PS A2 vaccine showed IHA titres ranged from 1/4 to 1/16.
Immunization with the whole cell vaccines or the heated culture
supernatant elicited responses to numerous antigens. Strongly reacting bands were seen
at major OMP bands of molecular mass 30 kDa and 42 kDa. Crude OMP-PS and
purified OMP-PS vaccines elicited responses to the major OMPs but not to the minor
bands seen with whole cell vaccinations. Antisera raised against leukotoxin did not
contain specificities against the OMPs and even when OMP-PS were added to it.
Table 7.3 Counts' of P. haemolytica A2 in the livers of unvaccinated control
mice and mice vaccinated with P. haemolytica A2 antigens after
challenge1".
Group Vaccine Vaccine Dose Mean count in liver





2.9 x 108 cfu/ml





Crude OMP-PS 10 /vg sialic
extract
4.147 NS










a - Counts = cfu expressed as log10 values
b - Challenge dose (1.02 x 107 cfu)
*
- When compared with the control group in the
Mann-Whitney Ranking Test
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Table 7.4. Counts" of P. haemolytica A2 in the livers of unvaccinated control mice
and mice vaccinated with P. haemolytica A2 antigens after challenge6.













2.9 x 108cfu/ml 5.901












Ovipast 2 ml 1.570 <0.002
Ovipast and 2 ml + 10/;g 2.860 <0.002
OMP-PS extract sialic
Leukotoxin 2 ml 5.847 NS
9 Leukotoxin and 2 ml + 10^g 2.904 <0.004
Purified sialic
OMP-PS extract
10 Unvaccinated - 7.219
control
a t. Counts = cfu expressed as log,0 values
b - Challenge dose (1.02 x 107 cfu)
*








45-* ■— .— 4-42 kDa
12 I 1 M ^
Figure 7.8. Immunoblot of P. haemolytica A2 whole cells reacted with the following
serum pools;
Lane numbers:
1. Heat killed organisms
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Figure 7.9. Immunoblot of P. haemolytica A2 whole cells reacted with the following
serum pools;
Lane numbers:
1. Heat killed organisms





7. Ovipast + Purified OMP-PS
8. Leukotoxin
9. Leukotoxin + Purified OMP-PS




The outer membrane protein-polysaccharide complex ofN. meningitidis
group B protected mice against challenge with P. haemolyica A2 (Chapter 7.2).
Further work was carried out to obtain similar preparations of OMP-PS from P.
haemolytica A2. In this study it was shown that that the antigen (or antigens)
responsible for mouse protection are present in the purified OMP-PS complex of P.
haemolytica A2 and N. meningitidis group B and OvipastR vaccine. The purified
complex was shown to be predominantly polysaccharide in nature compared to the
protein rich composition of crude complex. This was shown in the immunoblotting
results where the crude OMP-PS material demonstrated the presence of the same protein
components and responses to these are detected with the antisera raised against the
crude preparation vaccinates but the mice were not protected. Therefore the difference
must be in the response to the polysaccharide antigen.
Immunoblotting and PAGE examination of the protein profile has indicated
that the protein ofmolecular weight 42 kDa is an important antigen. This is the major
outer membrane protein band as been reported by other investigators (Squire et a/.,
1984; Donachie et a/., 1988 ).
The results also demonstrated that OvipastR vaccine alone or in
combination with purified OMP-PS complex has been shown to confer immunity to mice
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against A2 challenge as indicated by low total viable counts. In contrast, no protection
was observed in mice vaccinated with leukotoxin. The protection evident in the Ovipast
vaccinated mice may be explained by the presence of antigens in the vaccine which are
important in the protection while leukotoxin lacks some of these antigens.
Immunoblotting results showed that antisera raised against leukotoxin did not contain
specificities to OMP. Donachie (1993, unpublished results ) also showed that calves
responded serologically to vaccination with IRPs but not to leukotoxin. The
immunogenicity ofA2 IRP antigens has been demonstrated by Gilmour et al. (1991)
using cell surface extract of cells grown under iron restriction and expressing IRPs. In
a series ofexperiments to test the efficacy of the Ovipast IRP, it has been demonstrated
that the vaccine conferred protection on SPF lambs against A2 disease and significantly
reduced the incidence of disease, numbers of bacteria recovered and severity of lung
lesions (Donachie, personal communication).
This experiment showed that OMP-PS can confer protection in mice and
therefore that the protective antigen is present in this extract. Mice immunised with
purified OMP-PS complex vaccine ofP. haemolytica A2 developed humoral antibodies
detectable by IHA test and immunoblotting results showed that 42 kDa OMP of P.
haemolytica A2 seemed to be the immunogenic protein component and therefore most
essential for noncovalent binding to the capsular polysaccharide. The IHA antigen in the
purified OMP-PS complex material is carbohydrate in nature and is the important
antigen in the protection ofmice against challenge with P. haemolytica A2.
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CHAPTER 8.0 THE EFFICACY OF OMP-PS COMPLEX P.
HAEMOLYTICA A2 VACCINE IN SHEEP
Developments in Pasteurella vaccines are moving away from the use of crude
whole cell bacterins towards identification and incorporation of specific protective
antigens. These latter antigens have been used to enrich existing vaccines by culture
modification or by addition of purified components.The vaccines which protected mice
against P. haemolylica infection also protected SPF lambs, but not against serotype A2
infection (Gilmour et a!., 1979). The antigens from serotype A2 tend to be weak
immunogens. Sialic acid is a major component of A2 capsule and the failure of
previous attempts to immunise mice and sheep with capsular vaccines against A2
challenge could be due to poor anti-capsular response elicited by the vaccines. These
sialic acid polysaccharides in complex with outer membrane protein have shown
promising results when tested for their immunogenicity in mice ( Chapter 7).
The following experiments were conducted to study the immunogenicity of
crude and purified OMP-PS complex in conventional sheep and to determine the
possible contribution of this candidate antigen to Pasteurella vaccines.
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8.2 Materials and methods
Vaccine preparations and formulation: The vaccines were prepared as
described in the general Materials and Methods. The vaccines contained lyophilised
crude or purified OMP-PS complex of P. haemolytica A2; resuspended in distilled
water to contain a standard concentration of 10 /ug/ml sialic acid. Alumunium
hydroxide (Alhydrogel, Superfos Denmark) was added to all vaccines to a 0.27% final
concentration.
Experimental design: Three groups of 4 lambs aged 3 months and 3 groups
of ewes aged 2 years were used in this experiment. The sheep had been clinically
healthy and tested negative for Pasleurella spp. The ewes and the lambs were randomly
allocated to vaccine groups. Two vaccine preparations consisting of crude and purified
OMP-PS vaccines complex were administered to two groups in each age group. The
animals were vaccinated subcutaneously (2ml dose) on the lateral aspect of the middle
third of the neck at day 0 and booster given 4 weeks later. The remaining group of
lambs and ewes were sham-vaccinated and served as controls. The animals were grazed
together at pasture raised at Moredun for the duration of the experiment.
Passive mouse protection test: Thirty mice were used and divided into three
groups of ten. The mice in group 1 were inoculated intraperitoneally with 0.5 ml of
sheep sera raised against purified OMP-PS complex, the mice in group 2 were
141
inoculated intraperitoneally with 0.5 ml of sheep sera raised against crude OMP-PS
material and the last group were sham-vaccinated controls. One hour after inoculation
all the mice were challenged intraperitoneally with 2.1 x 107 cfu/ml P. haemolyticu A2
in gastric mucin. Six hours after challenged all the mice were killed and viable counts
were performed as described in general Materials and Methods.
Sheep sera: The animals were bled for serology by jugular venepuncture (10
ml vacutainers) on day 0 and at weekly intervals for 6 weeks. A pool of sera from SPF
lambs recovered from experimental P. haemolytica infection served as a reference
positive serum in the immunoblotting experiments (Donachie et ul., 1988).
Serological tests: IHA test, SDS-PAGE and immunoblotting were performed
according to the method described in the general Materials and Methods.
8.3 Results
The serum antibody titres of the adult sheep and lambs vaccinated with the
OMP-PS complex vaccine and the control groups (sham-vaccinated), measured in the
IHA test, plotted against time are shown in Fig.8.1-8.2. The purified OMP-PS vaccine
stimulated a highly significant (P<0.05) IHA antibody response to P. huemolyticu A2
in the adult sheep when compared to the crude OMP-PS vaccine and sham-vaccinated
group. Antibody levels increased quickly to a titre of 1:16 a week after primary
vaccination and again increased to a mean titre >1:96 after second vaccination and then
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Fig. 8.1. Mean IHA antibody response to P. haemolytica A2 capsule antigen

























Fig. 8.2. Mean IHA antibody response to P. haemolytica A2 capsule
antigen for lainbs vaccinated with crude OMP-PS and purified OiMP-PS
extract vaccines
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maintained thereafter. The adult sheep that were vaccinated with the crude OMP-PS
material had low levels oftitres (1:8) until week 3 and showed increased titre only after
secondary vaccination. Lambs appeared to have no response to the vaccines. The mean
serum antibody titre remained low (<1:4) throughout the study period.
The superior serological response in the group of ewes which received the
purified material compared to the crude complex vaccine group was maintained
throughout the subsequent six weeks periods. The mean serum antibody titres of the
sheep in the sham-vaccinated control groups remained almost constant (<1:8)
throughout the experiment.
The results of the mouse passive protection test are shown in Table 8.1. The
viable counts in the livers ofmice immunised with the purified OMP-PS complex vaccine
were significantly lower than the counts in the other 2 groups (p<0.004) indicating good
protection afforded by the vaccine.
The results of immunoblotting of sera from all the groups of vaccinated and
control sheep against P. haemolytica A2 whole cells antigens are shown in Figure 8.3.
Sera from vaccinated animals recognize numerous antigens in the A2 whole cells
indicating successful immunisation. There are strong reactions with all the sera from
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Table 8.1 Passive protection ofmice against P. haemolytica A2 challenge with










0.5 ml 1.500±0.006 <0.004
2 Crude
OMP-PS
0.5 ml 4.082±0.008 NS
3 Sham-
vaccinated
0.5 ml 4.809±0.003 NS
a - Counts = cfu expressed as log10 values
b - Challenge dose (2.1 x 107 cfu)
*
- When compared with the control group in the
Mann-Whitney Ranking Test
vaccinated group against the protein in the 42 kDa region. Although a strong reaction
in the sera from the vaccinated sheep in the 42 kDa was also demonstrated by the sera
from crude OMP-PS group but the sera did not protect the mice in passive protection
test. Instead the mice immunised with the sera from sheep vaccinated with the purified
OMP-PS were highly protected. Therefore the polysaccharide material which was










1 2 3 4 5










The results ofthis trial indicate that the purified preparation of OMP-PS complex
vaccine was most successful in enhancing the serological response. The complex was
immunogenic in adult sheep with induction ofhumoral anti-capsular antibody in IHA
test and with OMP in immunoblotting.
Previous results indicated that direct immunisation of mice with the complex
vaccine demonstrated significant protection against A2 infection. The sera from two-
year old sheep immunised with OMP-PS passively protected mice against A2 challenge.
Three-month old lambs immunised with the same vaccine did not respond serologically
and their sera did not passively protect mice.
The immunogenicity ofbacterial cell surface antigens has been studied carefully
as they are likely to be those which are important in conferring protection against
infection Although bacterial polysaccharides are often very antigenic, their
immunogenicity is dependent on such things as molecular weight, the dose of
polysaccharide given and their interaction with the imunological mechanisms of the host
(Jann and Jann, 1977). Our study had revealed that A2 capsular polysacharide non
covalently bound to OMP was immunogenic in older sheep.
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Since sialic acid, the only major amino sugar of P. hciemolytica A2, is also a
major constituent ofmammalian cell membranes and many animals glycoprotein, it is
possible that genetic immunologic tolerence to this polysaccharide is the cause of the
lack ofantibody response. The poor antibody responses in the young lambs are likely to
be due to self immune tolerance. In man, the polysialidated proteins that are found in
the embryonal and newborn brain tissue are identical to the repeating units of sialic acid
in N. meningitidis group B polysaccharide (Finne et al, 1982, 1983). The situation is
possibly the same with the young lambs, consequently the animals are tolerant to this self
epitope resulting in poor antibody response to purified OMP-PS ofP. haemolyica A2
complex vaccine.
The study has demonstrated that immunity and protection in sheep are not
confined to vaccination with live organisms, and that outer membrane protein-
polysaccharide complexes can act as very effective vaccines in mice and sheep. One
should be cautious, however in attempting to extrapolate the protective value of this
vaccine in a mouse models compared to sheep models.
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CHAPTER 9.0 A STUDY OF MACROPHAGE PHAGOCYTOSIS TO
DISTINGUISH BETWEEN ADHERENT AND
PHAGOCYTOSED P. HAEMOLYTICA A2
9.1 Introduction
Capsular polysaccharides have been extracted from cultures of P. hciemolytica
A2 complexed to outer membrane protein in high molecular weight form and shown
to be highly immunogenic in mice and adult sheep (earlier experiments). The capsular
polysaccharide is recognised as an important virulence attribute in preventing
phagocytosis and bactericidal serum activity.
Serum antibody is thought to exert several functionally significant biologic
roles such as bacterial opsonisation, agglutination of particulates, complement
activation, neutralisation of bacterial toxins and viruses and lysis of gram-negative
bacteria in the presence of complement (Hand et al., 1974). During acute respiratory
tract infection, there may be rapid influx of serum immunoglobulins into alveolar
spaces, thereby providing increased opportunities for interactions between specific
and nonspecific pulmonary defense mechanisms (Hunninghake et al., 1979). The
authors also showed that resident alveolar macrophages and PMN from
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the peripheral blood are the initial line of cellular host defense in the lower part of
the respiratory tract against inhaled bacterial agents. The defense against bacterial
pneumonia depends upon the numerical adequacy of phagocytes in the lower
respiratory tract, opsonisation of the bacteria, and effective intracellular killing of the
bacteria by the phagocytes (Horvitz, 1982). The purpose of this study was to
determine phagocytic response of ovine alveolar macrophages and murine peritoneal
macrophages to both opsonised and nonopsonised preparations of ultra violet-killed
P. haemolyica A2 in the present of antibody raised against crude and purified OMP-
PS complex antigens ofP. haemolyica A2.
9.2 Materials and Methods
Bacteria: An aliquot (0.5 ml) of P. haemolytica A2 was incubated overnight
in 10 ml nutrient broth at 37°C. Bacteria were inactivated by exposing to ultra violet
(UV) light for 3 h.
Fluorescence labeling of bacteria: Fluorescein thiocyanate (FITC)-labeling
of bacteria was conducted according to the method described by Drevets &
Campbell, (1991). Briefly UV-killed P. haemolytica were washed in PBS, then
labeled with FITC by incubation with 0.1 mg/ml FITC isomer 1 (Sigma Chemical
Co., UK) in 0.1 M NaHC03, pH 9.0 at room temperature for 60 min. Bacteria were
pelleted at 3500 g for 15 min., then washed free of unbound fluorochrome with PBS
and stored frozen at -20°C until used.
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Sera: Control normal mouse sera and sheep sera containing antibodies to
purified and crude OMP-PS ofP. haemolytica A2 and N. meningitidis group B were
obtained from the previous experiments.
Cells: Inflammatory peritoneal macrophages were obtained by injecting mice
intraperitoneally with 1 ml sterile 10% peptone water. Cells were harvested 48 h later
by peritoneal lavage with 10 ml cold, sterile Hank's solution. The cells were
resuspended in Hank's and counted in hemacytometer.
Sheep broncoalveolar macrophages (BAM) were recovered from lungs of
slaughtered, apparently healthy animals as described by Sutherland et al. (1983).
Sheep BAM were centrifiiged at 500 g, washed twice in Hanks and finally
resuspended in Hanks medium + 10 % dimethyl sulphoxide (DMSO) at 1 to 2 x 107
viable BAM/ml. BAM were stored in 1 ml aliquots at -70°C until required.
Aliquots of stored BAM were thawed, pooled and made up to a 20 ml volume
ofBAM suspension with Hanks. BAM were centrifuged at 500 g for 10 min and the
sedimented cells washed twice in Hanks and resuspended in 4 ml of Hanks medium
+ 10% FBS. A cell count and viability estimate were carried out. The suspension was
adjusted to 2 x 106 viable BAM/ml in Hanks + 10% FBS.
An aliquot (0.5 ml) ofBAM suspension was added to each polypropylene vial
containing P. haemolytica A2 organisms which were pre-opsonised with test sera.
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Two control samples containing bacteria with FBS also received BAM (non-
opsonised controls) and a further two control samples received 0.5 ml of Hanks
medium + 10% FBS (bacteria controls).
Phagocytosis assay: Phagocytosis assay was measured using a standard assay
as described by Czuprynski et al. (1984). Briefly, 2.5xl06 macrophages and 2.5xl07
FITC-labeled P. haemolytica A2 were mixed with the control and test serum and
diluted to 1 ml final volume in siliconised 12x7.5 mm bottles. The bottles were
incubated at 37°C for 30 min on a rolling shaker. Free bacteria were removed by
washing the cells three times with 2ml iced Hank's solution. The cells were
resuspended in 1 ml PBS with 5% foetal calf serum and 5 mM glucose. Cells were
held on ice prior to examination. After phagocytosis 100 aliquots ofmacrophages
in suspension were removed and mixed with ethidium bromide (EB). Then a 10 /j\
drop was immediately placed on a glass slide, and overlaid with a cover slip.
Phagocytosis of FITC-labeled bacteria was visualised with a fluoresence microscope
(Olympus PM-20, Japan) using a 520 nm FITC filter under oil immersion (1000 X)
and quantified by counting 40 consecutive individual macrophages with one or more
associated bacteria.
Photographs were taken through the fluorescence microscope with a Olympus
BX-20 camera using Kodak Ectachrome 1600 EES 135 film. Original magnification
ofphotographs was 240 X.
9.3 Results
The group mean of macrophages with internalised and externalised FITC-
labeled P. haemolytica A2 coated with anticapsular antibodies for each test group
are presented in Table 9.1-9.2. The number of P. haemolytica A2 organisms
inoculated into suspension was 2.5 x 107 cfu/ml. The bacteria to macrophage ratio
was approximately 10:1. The mean number of mouse peritoneal macrophages that
showed phagocytosis of opsonised bacteria was significantly higher (p<0.05) when
the antisera used for opsonisation was taken from purified OMP-PS immunised
animals (p<0.01). The macrophages which were incubated with bacteria and serum
raised against crude OMP-PS complex antigens and serum from sham-vaccinated
mice were unable to phagocytose bacteria. The bacteria were not opsonised thus
were not phagocytosed and a high proportion (72.5%) of the bacteria remained
extracellular. In contrast the mouse peritoneal macrophages internalised 84.3% of the
bacteria incubated in the serum raised against the purified preparation of OMP-PS
complex. When the antisera used for opsonisation was taken from sham-vaccinated
mice the phagocytic activity was poor. Eighty five percent of the bacteria remained
extracellular.
Plate 9.1 and Plate 9.2 showed FITC-labeled P. haemolytica A2, which by
themselves fluoresce bright green and then fluoresced a bright orange after the
addition of ethidium bromide. Plate 9.3 showed mouse peritoneal macrophages with
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Table 9.1. Adhesion versus phagocytosis of /'. haemolytica A2 by murine
peritoneal macrophages.
Sera Mean no. macrophage Mean no. macrophage %






I l±2.1 29±2.1 27.5±5.2
Sham-
vaccinated
7.33±0.67 32.67±0.67 18.33± 1.7
Table 9.2. Adhesion versus phagocytosis of /'. hnemolytica A2 by sheep
alveolar macrophages.
Sera Mean no. macrophage Mean no macrophage %
with intracellular bacteria with extracellular bacteria Phagocytosis
Purified 27.671:1.5 12.331 1.5 69.1913.6
OMP-PS
Crude 7.33±0.67 32± 1.2 20*2.9
OMP-PS
Sham- 6.33*0.88 33.67±0.88 15.83*2.2
vaccinated
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Plate 9.1. Flourescent antibody reactions. Cells of P. haemolytica A2 were
treated with antibody conjugated with fluorescein isothiocynate
(F1TC), which fluoresces green (magnification x 240)
Plate 9.2. Fluorescence micrographs of FITC-labeled P. haemolytica A2
w ith ethidium bromide (EB) a''ded (magnification x 240)
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Plate 9.3. Fluorescence micrograph of macrophages and phagocytosed
FITC-labelled P. haemolytica A2 with ethidium bromide (EB) added.
Intracellular bacteria remain green while extracellular bacteria
fluoresce orange( magnification x 240)
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extracellular (orange) and intracellular (green) FITC-labeled P. haemolytica A2.
The results of the phagocytic activity of sheep alveolar macrophages were in
agreement with that obtained with the mice experiment (Table 9.2). The mean
number of sheep alveolar macrophages that showed phagocytosis of opsonised
bacteria was significantly higher when the antisera used for opsonisation was taken
from purified OMP-PS immunised animals (p<0.05). Phagocytosis of opsonised
bacteria was poor when the antisera used for opsonisation was taken from crude
OMP-PS or sham-vaccinated animals.
9.4 Discussion
The study using antibody-mediated phagocytosis assay was conducted to
determine the level of opsonising antibodies to OMP-PS of P. haemolytica A2
present in the sera of mice and sheep vaccinated with the purified and crude
preparation of the OMP-PS complex. The study has demonstrated that P.
haemolytica A2 are readily labeled by FITC and when exposed to ethidium bromide
the green to orange colour shift occurs.
Ultra violet-killed FITC-labeled P. haemolytica A2 was used in this assay thus
avoiding the alteration of bacterial surface proteins important in phagocytosis.
However, Drevet & Campbell (1991) showed that there was no difference between
FITC-labeled live versus heat-killed Listeria monocytogenes with respect to the
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percentage ofmacrophage associated bacteria which were internalised.
Sera from vaccinated sheep or mice which received purified OMP-PS antigen
had high specific serum antibody titres to P. haemolytica A2 and significant increased
opsonising activity than those ffom animals which were a) unvaccinated or b)
vaccinated with crude complex.
The correlation of high percentage of opsonophagocytic activity and high IHA
titres in the sera conferring protection in mice against P. haemolytica A2 challenge
suggest that capsular antibody is important. The study also indicated that the sera
from mice vaccinated with meningococcal group B vaccine poorly opsonise P.
haemolytica A2 ( results not shown). This in in agreement with the findings of
Donachie et a/., (1991, unpublished data) who reported that the sera from sheep
vaccinated with meningococcal group B vaccine do not opsonise P. haemolytica A2.
The author suggest that the mechanism of phagocytosis might be species specific in
vitro.
»
Macrophage phagocytosis assay using fluorescence microscopy has proved
useful as an experimental tool for evaluating serum opsonic capacity and phagocytic
cell function. The assay allows discrimination of bacteria which are bound to the
external surface of a cell from those internalised by it. Measurement of internalised
and externalised cell by fluorescence microscopy allows the asessment of the
intracellular and opsonophagocytic functions of macrophages in vitro. The method
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was used for studying phagocytosis of fluorescein-labeled Listeria monocytogenes by
inflammatory mouse peritoneal macrophages (Drevets & Campbell, 1991). The
results have indicated that this macrophage phagocytosis assay can be applied to P.
haemolytica. This assay is simple, sensitive and reproducible and can be used to
obtain information about phagocytic cell function or serum opsonic antibody content.
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CHAPTER 10.0 GENERAL DISCUSSION
The aims of this study were to identify the prevalence and distribution of
Pcisteurellci haemolytica serotypes causing pneumonic pasteurellosis in sheep and goats
in Malaysia, assess the efficacy of a novel P. haemolytica iron-regulated protein (IRPs)
vaccine in field trials and to isolate, characterise and assess the immunological
significance of the polysaccharide capsule ofP. haemolytica A2.
This general discussion examines the extent to which the original aims of this
study have been realised, the questions which remain to be answered, and makes
suggestions about the type of the research which may in the future provide additional
useful information.
Pneumonic pasteurellosis remains a common and serious problem to the sheep
and goats industry in many livestock producing countries including Malaysia. In the UK,
pasteurellosis caused by P. haemolytica is the most important respiratory disease and
is one of the most common bacterial infections of sheep ( Gilmour and Gilmour, 1989).
It has been estimated that not a single farm in Malaysia is free from the problem. The
incidence of the disease is increasing and there is continuing need for vaccines to be used
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in its control. However, the vaccines that were available to farmers are of questionable
value and since protection of sheep by the Pasteurella vaccines are serotype-specific
(Gilmour ei al., 1983) there is a possibility that differences which may be present
between the imported vaccine strains from the Malaysian field strains result in this poor
efficacy. Therefore this thesis started with an epidemiological study to identify the
serotypes of P. haemolytica involved in disease and determine their relative prevalence
in the country. The dominant field strains isolated were compared with the UK strains
for protein and LPS profiles in SDS-PAGE.
The serotyping study indicated that there was little difference in the relative
frequency of occurence of A serotypes in the UK and in Malaysia. The serotypes
isolated largely agree with the recognised pattern in sheep in the UK (Fraser ei al.,
1982), Serotype A2 was by far the most common and the other A serotypes did not
differ significantly in order of prevalence. However T biotypes appear to be rare in
Malaysian isolates possibly because they are associated with temperate latitudes
(Gilmour & Gilmour., 1989). The serotype distribution for the A serotypes in the
present study is also similar to that found in a survey of ovine pasteurellosis cases at
MRI during 1982-1993 ( Quirie, 1994, unpublished data) and also in Northern Ireland
(Ball et al., 1993).
When electrophoretic protein and lipopopolysaccharide profiles of some common
strains from both countries were compared by SDS-PAGE analysis there appeared to
be no significant differences among the strains. Four to five major protein bands with
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about twenty minor bands were shown to be present. The lipopolysaccharides profiles
were of rough-type and designated type 3 (Davies et al., 1992). This in agreement with
the earlier work by reported by Adlam et al., (1989). However, it is in disagreement
with the findings ofDavies et al, 1992 who showed that some isolates ofA serotypes
has smooth-type LPS. These workers used a different method of LPS extraction and
different gel concentrations.
The epidemiological results may be of significance and the information can be
used to design relevant control programmes involving management and disease
prevention methods against ovine and caprine pasteurellosis in Malaysia as they give an
indication of the serotypes most commonly found in pneumonic cases in the field. The
study has indicated that British strains can be used in the vaccines for control of
pasteurellosis in Malaysian farms.
Vaccines containing cell-free extract ofofP. haemolytica serotypes Al, A6 and
A9 have been shown to protect SPF lambs against experimental pasteurellosis caused
by these serotypes (Gilmour et al., 1983). The results of similar vaccine experiments
with the A2 serotype were not succesful. Although some protection was observed this
was never greater than 50% or often less (Gilmour et al., 1983). An effective vaccine
against A2, the most common serotype associated with sheep disease throughout the
world is required.
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New vaccines incorporating iron-regulated proteins (IRPs) have been developed.
Molecular analyses ofP. haemolytica cells, recovered from infected lambs, revealed the
presence of these novel surface antigens expressed in vivo growth in the host. They
were shown to be IRPs which are inducible in iron-deficient laboratory media (Donachie
& Gilmour, 1988). Incorporation of IRPs antigens into SSE vaccines for P. haemolytica
A2 conferred significant protection against A2 challenge confirming their importance in
immunity (Gilmour et al., 1991). Subsequently, the efficacy of these novel vaccines
containing 5As and 4Ts ofPasteurella haemolytica strains grown under restricted iron
has been studied extensively in the SPF sheep models. Under field conditions, not many
studies have been conducted. An extensive study using this novel vaccines were
conducted in 2 large and 2 small farms in Malaysia involving 1000 animals. In this study
the magnitude ofantibody response against 35 kDa IRP and anti-Al capsule measured
by ELISA and EHA in animals immunised with OvipastR-9-IRP vaccine were examined.
The IRP vaccine elicited serum antibody responses against all the antigens tested
confirming the immunogenicity of the vaccine components. Good antibody responses
against the 35 kDa IRP antigens were associated with pure iron-regulated OMP
components incorporated in the vaccines. Antibody response to 35 kDa IRP similar to
this but using SPF lambs have been demonstrated by other investigators (Gilmour et al.,
1991). An ELISA to measure antibodies to a 35kDa IRP protein was used in most
immunisation studies with IRP vaccine in SPF sheep models. This protein is used as
general marker antigen for IRPs as it is assumed that all IRPs are produced in concert
(Donachie, personal communication). However, it is clear from report that it is not
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specific for P. haemolyica and in many situations the sera from sheep from areas thought
to be free from P. haemolytica infection show high ELISA readings.
Capsular polysaccharide is found in large quantitities in the surface ofbacteria
and considered an important virulence factor ofP. haemolytica, perhaps explaining the
predominance of serotypes A2 and A1 in disease. Therefore high levels of IHA titres
were demonstrated in the vaccinated and control animals. Antibody response to anti-Al
capsule is poor and this could be explained by the fact that our assay used an antigen
capture system using monoclonal antibodies to A1 capsule, making it more specific.
The results so far obtained with the efficacy study of the new IRPs vaccines
were encouraging and are in agreements with that of Donachie et al. (1984a) who
demonstrated that high IHA and ELISA titres of antibodies to serotype antigens ofA2
were obtained after infection with live A2. In SPF lambs the highest antibody responses
also occur after challenge with live organisms (personal observation).
This field study investigated the immunologic responses to the these various
antigens but no correlation to protection was investigated. As it is not possible to
produce pneumonic pasteurellosis regularly in conventionally reared lambs by exposure
to aerosols ofP. haemolytica, the assessment of the effect of vaccination was based on
the measurement of the serum antibody titres. A high degree of correlation between
IHA antibody responses and protection has been demonstrated (Gilmour et al., 1980).
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Gilmour etal. (1983) found that the IHA titre of serum from sheep immunised with P.
haemolytica SSE correlated on a group basis but not an individual basis with protection.
The results of the same correlation between high anti-Al capsular titres and protection
have also been implicated in other studies (Gilmour et al., 1979; Confer etal., 1989).
Similar data for usefiilless of 35 kDa IRPs in the induction ofprotective immunity in
pneumonia of sheep, have shown positive correlation between antibody titres and
protection against disease (Gilmour et al., 1991). The exact mechanisms by which
antibodies against IRPs effect protection is at present unknown, but they may prevent
iron uptake by the bacterium by blocking siderophore or transferrin binding, thereby
reducing its ability to replicate quickly enough to cause disease.
Under field condition, a good antibody response could be achieved in animals
immunised with the vaccines. However, multiple doses are required to achieve an
optimal level of efficacy with this vaccine. When serological monitoring was extended
to 4 months it was found that the serum antibody titres were almost the same for all the
groups of vaccinated and control lambs. However group numbers were too small for
definitive assessment.
To prevent loss from clinical illness, vaccination against pasteurellosis on an
individual herd level is widely applied in enzootically infected regions in Malaysia.
However until now, vaccination with traditional vaccines has not been able to cause a
major reduction in the spread of the disease. The efficacy of the vaccination with a new
IRP vaccine was evaluated by monitoring for antibodies against 35 kDa IRP, anti-Al
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capsule and IHA antibody. In the trial region this vaccination greatly reduced the
incidence of the disease.
In Malaysia, in most flocks that were vaccinated to prevent clinical disease, the
lambs were vaccinated only once. Unless the animals were given booster vaccination,
the titres of the maternally derived antibodies were low. One vaccination was far less
effective in reducing P. haemolytica /'nfection against natural challenge than two
vaccinations (data not shown).
This study showed that using Ovipast-P-IRP*vaccine and monitoring for relevant
specific antibodies the effect of vaccination on the incidence of pasteurellosis in a
population can be seen.
Another candidate for a future Pasteurella vaccine is the capsular polysaccharide
antigen ofP. haemolytica A2. The capsule is a linear heteropolymer of oc-(2-? 8)-linked
N-acetylneuraminic acid. The capsule is a virulence factor of P. haemolytica A2 and
similar to other capsulated pathogens, serves to protect the organism by antiphagocytic
mechanism. An outer membrane protein-polysaccharide (OMP-PS) complex was
succesfully prepared from an ovine isolate of P. haemolytica serotype A2 by
precipitation from log phase culture supernatant and subsequent purification by column
chromatography as previously described by Moreno et al., 1985 in preparing OMP
complexed to group B polysaccharide ofN. meningitidis. The results have shown that
the optimum production of the complex was determined to be in 6 hour culture and
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comprised of protein and polysaccharide (4:1 w/w) and low in lipopolysaccharide
content. This is in agreement with earlier work reported by Moreno et al. (1985) who
showed that the OMP complexed to group B polysaccharide ofN. meningitidis revealed
low levels ofnucleic acid and LPS content and the complex could be obtained optimally
in 6 hour culture.
The importance of a purified OMP-PS complex as a protective antigen was
demonstrated in mice and sheep. The complex was immunogenic in mice and adult
sheep with induction of humoral anti-capsular antibody as measured in the indirect
haemagglutination (IHA) test and with OMP in immunoblotting. Direct immunisation
of mice with the complex vaccine demonstrated significant protection against A2
infection. Induction ofanti-capsular antibody and correlation with protection were also
demonstrated by other investigators (Gilmour et al., 1979; Confer et al., 1989).
However, Gilmour et al. (1983) reported that although cell extract vaccines of some
serotypes ofP. haemolytica were protective in SPF lambs, inactivated A2 antigens were
relatively ineffective. The low immunogenicity of the capsule of A2 serotype is thought
to be due to its chemical structure, an a-(24j8)-linked polymer ofN-acetylneuraminic
acid which was identical to the colominic acid polymers ofN. meningitidis group B. This
colominic acid has a very low immunogenicity in rabbilts and man, and is thought to be
due to identical chemical structures on certain gangliosides on the surface of host cells
(Glode et al., 1977; Kasper et al., 1973; Lifely et al., 1987), loose configuration and
sensitivity to host neuraminidases (Lifely at al., 1987 ) may all contrbute to decrease
immunogenicity. The bacterial polymer is thus not identified as foreign to the host,
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permitting evasion of its immune system. As a consequence, the capsular polysaccharide
does not induce specific antibodies. However, the capsular polysaccharide noncovalently
complexed with outer membrane protein has shown promising results when tested in
mice and adult sheep.
The sera from two-year old sheep immunised with OMP-PS passively protected
mice against A2 challenge. This is in agreement with earlier work reported by Moreno
et al., 1983 who demonstrated that monoclonal antibodies against meningococcal
polysaccharide group B protected mice passively against challenge with live organisms.
Three-month old lambs immunised with the same vaccine did not respond serologically
and this sera did not passively protect mice. Adlam et al. (1987) also reported that the
age of animals at time of vaccination is important as he demonstrated the non-
responsiveness of young lambs to purified antigens of P. haemolyticci. The poor
antibody response in the young lambs are likely to be due to immune tolerance. In
human, the polysialidated proteins that are found in the embryonal and newborn brain
tissue are identical to the repeating units of sialic acid in N. meningitidis group B
polysaccharide (Finne et al., 1982, 1983). The situation is possibly the same with the
young lambs, and consequently, the animal being tolerant to this self epitope results in
poor antibody response to purified OMP-PS ofP. haemolyica A2 complex vaccine.
In vitro studies using ovine and murine macrophages indicated that the
mechanism of protection is antibody mediated phagocytosis as the opsonophagocytic
activity of immune sera could be demonstrated. This is in agreement with the work
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reported by Brodgen et al. (1989) who suggested that correlation of anti-capsular
antibody and protection may operate by inhibiting adhesion ofbacteria to the mucosal
surface as well as augmenting phagocytosis. The correlation ofhigh opsonic activity and
high IHA titres in the sera with protection ofmice against P. haemolytica A2 challenge
suggest that capsular antibody is important. It has been reported that sera from sheep
vaccinated with meningococcal group B vaccine do not opsonise P. haemolytica
(Donachie, 1991 unpublised data). The author suggested that the phagocytic mechanism
might be species specific.
Previous work on P. haemolytica showed that serotype A2 antigens, heat killed
cells together with cellular extracts produced by treatment with sodium salicylate were
of reduced immunogenicity compared to similar antigens from other A serotypes. The
results presented here demonstrate that solid protection against serotype A2 is produced
in mice receiving sheep sera containing antibody against purified OMP-PS complex of
P. haemolytica A2 and its potential to immunise adult sheep and suggests that passive
protection of lambs against A2 infection is obtainable.
The protective property of the P. haemolytica A2 OMP-PS complex suggests
that it should be considered as a possible vaccine component for sheep vaccines although
the preparation procedure might be too elaborate for commercial firms.
The traditional approach to vaccine formulation has been to incorporate all of
the most commonly isolated serotypes but this leads to complex formulations which
imposes a veiy heavy antigenic load on vaccinated animals. The identification of the
shared protective antigens is therefore important in the development and improvement
of this type of vaccine as their inclusion will reduce the overall quantity of the antigen
required.
With regard to future research, a detailed understanding of the exact pathway
by which P. haemolytica obtain iron from transferrin is necessary to allow the
production of even more effective vaccines based on IRPs. In addition, because natural
polysaccharides production is low, some means of improving its yield has to be found
if it is to be an economic component of vaccines. On the evidence of these results, it
would seem that new Pasteurella vaccine should contains IRPs, capsule, leukotoxin and
perhaps LPS if they to confer a very high measure of immunity.
Inactivated whole cell Pasteurella vaccines will continue to be the major type
of vaccine available but with the rapid discovery and purification of important
immunogens, through the use of recombinant DNA techniques in particular, antigenically
well defined vaccines should start to emerge. When these are combined with the greater
knowledge of the host's immune response and the immunopotentiating power of the new
adjuvants the "second generation" of super vaccines will have arrived. However in the
harsh world of veterinary and agricultural economics these vaccines will have to be
affordable and inevitably compromises will be encountered on the way to their final
application.
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To conclude, the major points arising from this work are: there was little
difference in the relative frequency of occurence and electrophoretic protein and LPS
profiles ofA serotypes in the UK and Malaysia; the new P. haemolytica IRP vaccine
generated an immune responses as measured in ELISA and IHA tests and appeared to
correlate with protection against pasteurellosis; and the potential af a P. haemolytica A2
OMP-PS complex vaccine to immunise adult sheep was demonstrated and suggests
that passive protection of lambs against A2 infection is obtainable.
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PROTECTION OF MICE AGAINST PASTEURELLA HAEMOLYT1CA A2 CHALLENGE
USING A PROTEIN/CAPSULAR POLYSACCHARIDE COMPLEX VACCINE
M. Mohamad1 and W.Donachie2
'Livestock Research Division, MARDI,
G.P.O. Box 12301,50774 Kuala Lumpur, Malaysia.
2Moredun Research Institute, Edinburgh, Scotland, UK
SUMMARY
An outer membrane protein-capsular polysaccharide (OMP-PS) complex was prepared from an
ovine isolate of Pasteurella haemolytica serotype A2 by precipitation from log phase culture supernatant
and subsequent purification by column chromatography. This complex comprised protein and
polysaccharide (4:1 w/w) with traces of lipopolysaccharide. The purified OMP-PS vaccine stimulated an
antibody response to capsule in the indirect haemagglulination (IHA) test and to OMP in
immunoblotting. In contrast to crude OMP-PS and whole bacteria vaccines the purified complex
protected mice against challenge with P. haemolytica A2.
INTRODUCTION
Pneumonia associated with Pasteurella
haemolytica is a major cause of economic loss to the
sheep and goat industry in Malaysia. Protection against
the A2 serotypes, which is the predominant ovine
isolate from field cases, has proven difficult to
demonstrate with cell extract vaccines. Serotype A2
has a capsular structure; a(2-*8)-linked N-
acetylneuraminic acid identical to the colominic acid of
Neisseria meningitidis group B and Escherichia coli K1
and is known to be poorly immunogenic (1).
Inoculation with monoclonal antibody against N.
meningitidis group B capsule and outer membrane
protein-capsular polysaccharide (OMP-PS) complex
meningococcal vaccine protected mice against
challenge with N. meningitidis group B and P.
haemolytica A2 strains (3,6). The result prompted
research to formulate P. haemolytica vaccine with a
similar composition to meningococcal vaccine to
evaluate its efficacy against experimental
pasteurellosis.
MATERIALS AND METHODS
Bacteria and growth condition: Pasteurella
haemolytica A2 (strain EO 200) was grown in nutrient
broth (Gibco No.2) for 18 h at 37°C. Large quantities
of bacterial cells for capsule extraction were produced
by inoculating 5 litres nutrient broth with 50 ml seed
broth and incubating at 37°C for 6 h on orbital shaker.
Indirect haemagglutination (IHA) test: The
rapid method described by Fraser el al. (5) was used.
Mouse protection model: C57 black mice (6-8
wk old) were used for immunisation and protection (4).
Preparation of the OMP-PS complex vaccine:
Preparation of crude and purified complex was based
on the method used by Moreno, et al. (6) for purifying
OMP-PS complex from N. meningitidis group B.
Heat-killed organisms and extract: This
preparation was based on the procedure used by
Donachie (2).
Meningococcal group B vaccine: This was
kindly donated by Dr. R. Lifely, Wellcome Biotech.
Kent, UK. The typical composition of vaccine complex
is 48.6% sialic acid, 46.8% protein and 4.1%
lipopolysacch;iride (LPS).
Immunoblotting: Whole cells preparations of P.
haemolylica were separated by sodium dodecyl
sulphate - polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred on nitrocellulose paper
(Sarlorius). The blots were probed with mouse antisera
and sheep anti-mouse IgG. HRP conjugate was used to
detect bound mouse antibodies.
RESULTS
The composition and yield of the OMP-PS
complex preparation are shown in Table 1. Assay of
the serum antibodies of mice immunised by the purified
OMP-PS in the IHA test indicated high litres to A2 in a
number of mice. The litres range from •/,2g to V2J6-
Significanl protection (P<0.005) was conferred on
mice immunised with the purified OMP-PS complex
and meningococcal group B vaccine (Table 2). Sera
from vaccinated and control mice were examined in
immunoblots against P. haemolytica A2 cells to
determine the antibody response to cellular proteins. A
very strong response was observed at around 42 kDa
and 26 kDa.
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Table 1. Protein and sialic acid determined in a preparation of OMP-PS complex of P. haemolylica serotype A2
Preparation , Protein (nig/ml) Sialic acid (mg/ml) Ratio of protein/sialic acid
Crude OMP-PS complex 1.1 0.72 1.5
Purified OMP-PS complex 0.08 0.02 4.0
Table 2. Counts* of P. haemolytica A2 in the livers of unvaccinated control mice and mice vaccinated with P.
haemolylica A2 antigens after challengeb.
Group Vaccine Vaccine Dose Mean count in liver
after 6 h (cfu)a
P*
1 Heat killed organisms 2.9 x 108 cfu/ml 4.499 NS
2 Heated culture'extract 2.9 x 108 cfu/ml 4.298 NS
3 Crude OMP-PS complex 10 pg sialic 4.147 NS
4 Purified OMP-PS complex 10 pg sialic 1.253 <0.002
5 Meningococcal gp.B vaccine 1 Mg 1.803 <0.005
6 Unvaccinated control 5.494
Counts = colony forming units (cfu) expressed as log values
Challenge dose (1.02 x 10' cfu)
When compared with the control group in the Mann-Whitney Ranking Test
DISCUSSION
Significant protection (P<0.005) against
P. haemolylica A2 infection was conferred on mice by
a vaccine containing purified OMP-PS complex. In
contrast, the crude complex and the heat-killed whole
bacteria vaccines did not give significant protection. A
similar level of protection against A2 challenge has
been demonstrated previously in mice injected with
meningococcal group B vaccine (3). The purified
OMP-PS complex stimulated an antibody response to
capsule in the 1HA test and to OMP in immunobTotting.
Immunoblotting of this sera demonstrated strong
responses to OMP with apparent molecular weights of
42 kDa and 26 kDa. This experiment has shown that
purified OMP-PS can act as a very effective vaccine in
mice against challenge with A2. Further studies are
now in progress to establish the immunogenicity of this
complex in sheep.
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PREVALENCE OF Pasleurella haemolytica SEROTYPES ISOLATED FROM
OVINE AND CAPRINE PASTEURELLOSIS IN MALAYSIA
1 M. Mohamad, M. Quirie and \V. Donachie2
1 Livestock Research Division, Malaysian Agricultural Research and
Development Institute (MARDI), G.P.O. Box 12301,
50774 Kuala Lumpur, Malaysia
JMoredun Research Institute, Edinburgh, Scotland, UK
Pasteurellosis due to infection with Pasteurella haenwlytica or P. multncida
are major diseases of ruminants of widespread geographical importance. The disease
causes serious economic loss to many major livestock producing countries. Prevention
of pasteurellosis has proven difficult. While some efforts have been directed towards
minimising exposure to some factors associated with the disease, vaccination is
accepted as the most effective and practical method of control.
To make a vaccine specifically intended for sheep and goats in Malaysia it is
important to establish the prevalence of diferrenl serotypes in the country. The purpose
of the present study was to examine the serotype strains of ovine and caprine origin
submitted for serotyping at Morcdun Research Institute, Edinburgh, UK and to
determine the range of serotypes for the year 1989-1991.
The strains submitted had been isolated at MARDI, Universiti I'ertanian
Malaysia and Veterinary Research Institute from sheep and goals throughout Malaysia
which were either clinically abnormal or had pathological condition at postmortem.
Strains were received on blood agar plates or slopes or frecze-dried and were
serotyped either directly from the original culture or after subculture on 5% sheep
blood agar. Strains were serotyped by a rapid indirect haemngglutinalion method as
describe^ by (2).
A total of 215 strains were submitted for serotyping (Table 1). The
predominant serotypes were A2, A9, A7 and A1 (38.5%, 16%, 14% and 13%
respectively). Three biotype A serotypes (A5, A6 and A I 1) were isolated in smaller
number. The biotype T was very rare (only 2% ). Fourteen percent strains were not
typable by the indirect haemagglutination method.
P. haenwlytica biotype A serotype 2 has been found to be the most common
serotype isolated from sheep and goat pneumonic pastcurellosis in Malaysia.The
serotype A2 was also the most prevalent serotype recovered from sheep farms in the
United Kingdom, (5) and New Zealand (6). Of the 215 isolates of P. haemolylica, 32
(15%) were untypable . This is typical of such surveys, e.g (1) and (3) found 12%,
28% and 34% respectively of their isolates were untypable.
The range of serotypes isolated from lungs suggests that all the common
serotypes should be included in vaccines against pneumonic pasteurellosis since
immunity is serotype specific (4). It is necessary to monitor continously the prevalence
of the various serotypes and to investigate the pathogenicity of new scroptypes strains
in order that the appropriate major serotypes can be incorporated in vaccines.
Acknowledgement. - We are indebted to the University l'ertanian Malaysia and
Veterinary Research Institute who referred strains.
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Table 1. The prevalence of serotypes of P. haemolytica isolated from sheep and
goats pasteurellosis in Malaysia.
Serotype 1989* 1990 1991 Average
A1 7 11 28 15
A2 14 36.5 55 35
A5 7 - - 2
A6 7 - - 2
A7 . 1 1 14 8 11
A 9 36 7 - 14
All - 2 - <1
T3 7 - - 2
IJT 1 1 27 9 15
otal Strains Typed 80 50 85 215
*
- Expressed as a percentage of the total number of strains examined.
1) Bibcrstein, E.L. and Thompson, D.A. (1966). J. Comp. Pathology 76: 83-94
2) Eraser, J., Donachie, W.; Quiric, M. and Gilmour, N.J.L. (1983). Journal of
Clinical Microbiology 18: 206
3) Gilmour.N.J.L., Thompson, D.A. and Eraser, J. (1974). Res. Vet. Sci. 17:
413-414
4) Gilmour, N.J.L., Martin, W.B., Sharp,J.M.,Thompson, D.A and Wells, P.W.
(1979). Veterinary Record 111: 15
5) Gilmour.N.J.L., Brodie, T.A. and Holmes, P.M. (1982). Veterinary Record 111:
512




Fig. 5.0 Map showing locations of; a) Laboratories where /'. haeuwlydca
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Table D (Data from Chapter 5.0)
Mean IHA antibody response to P. haemolytica antigens in sheep vaccinated
with Ovipast-9-IRP vaccine.
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Table E (Data from Chapter 5.0)
Antibody reponse to P. haemolytica A2 35 KDa IRP in sheep vaccinated with
Ovipast-9-IRP vaccine
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Table F (Data from Chapter 5.0)
Antibody response to P. haemolytica anti-Al capsular antigen in sheep
vaccinated with Ovipast-9-IRP vaccine
FARM A FARM B






































Table G (Data from Chapter 5.2)
Serum IHA titres (a), antibody response to 35 KDa IRP of P. haemolytica
A2 (b)and A1 capsular antigens (c) in sheep vaccinated with Ovipast-9-
IRP vaccine in challenge exposed experiment.





































Table H (Data from Chapter 7.2)
Counts of P. haemolytica A2 in livers of control mice and mice
immunised with monoclonal antibodies with high 1HA activity (mAb






Table I (Data from Chapter 7.2)
Counts (logio)of P. haemolytica A2 in livers of control mice and mice





Table T (Data from Chapter 8)
Serum IHA antibody litres of adult sheep vaccinated with crude and
purified OMP-PS complex vaccines and the sham-vaccinated group.
Time OD at 492 nm
Week Crude OMP Purified OMP Sham-vaccinated
0 9.5 0.5 8
1 9.5 1 4.5
2 9.5 12.5 2
3 10.5 13 2
4 24.5 20 1.5
5 24.5 52 1.5
6 40.5 96 5.5
Table K (Data from Chapter 8)
Serum antibody titres of the lambs vaccinated with crude and purified
OMP-PS complex vaccines and sham-vaccinated group.
Time OD at 492 nm
Week Crude OMP Purified OMP Sham-vaccinated
0 2 2 2
1 2.5 2.5 2
2 2 2 2
3 2.5 2.5 2
4 3 2.5 2
5 2.5 2.5 2
6 2.5 3 3
